Androgen receptor modulators and methods of use thereof
Tricyclic compounds targeting the androgen receptor's N-terminal domain provide a novel therapeutic strategy for prostate cancer, effectively inhibiting AR activity and tumor growth in castration-resistant prostate cancer.
Patent Information
- Application Number
- JP2021520575
- Authority / Receiving Office
- JP · JP
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2019-06-05
- Filing Date
- 2019-10-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-10-18
AI Technical Summary
Current treatments for prostate cancer, particularly metastatic castration-resistant prostate cancer, are inadequate as they fail to effectively target androgen receptor (AR) activation mechanisms, including constitutively active AR splice variants that are resistant to traditional antiandrogens.
Development of tricyclic compounds that modulate the androgen receptor (AR), specifically interacting with the N-terminal domain (NTD) to inhibit AR activity, providing an alternative therapeutic approach.
These compounds demonstrate potential in reducing prostate-specific antigen (PSA) levels and inhibiting tumor growth in preclinical models, offering a new treatment option for prostate cancer resistant to conventional therapies.
Smart Images

Figure 0007581192000243 
Figure 0007581192000244 
Figure 0007581192000245
Abstract
Description
[Technical Field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Provisional Patent Application No. 62 / 747,209, filed October 18, 2018, U.S. Provisional Patent Application No. 62 / 803,516, filed February 10, 2019, and U.S. Provisional Patent Application No. 62 / 857,516, filed June 5, 2019, the entire disclosures of which are incorporated herein by reference for all purposes.
[0002] The present disclosure generally relates to tricyclic compounds and their use for treating various indications.In particular, the present disclosure relates to tricyclic compounds and their use for treating various cancers, for example, prostate cancer, for example, including but not limited to primary / localized prostate cancer (newly diagnosed), locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic prostate cancer, metastatic castration-resistant prostate cancer (CRPC) and hormone-sensitive prostate cancer.The present invention also relates to tricyclic compounds and their use for regulating AR activity, including truncated androgen receptor (AR). [Background technology]
[0003] Androgens mediate their effects via the androgen receptor (AR). Androgens play a role in a wide range of developmental and physiological responses, and are involved in male sexual differentiation, maintenance of spermatogenesis, and male gonadotropin regulation (RK Ross, GA Coetzee, CL Pearce, JK Reichardt, P. Bretsky, LIN Kolonel, BE Henderson, E. Lander, D. Altshuler & G. Daley, Eur Urol 35, 355-361 (1999); AA Thomson, Reproduction 121, 187-195 (2001); N. Tanji, K. Aoki & M. Yokoyama, Arch Androl 47, 1-7 (2001)). Several lines of evidence suggest that androgens are associated with the development of prostate carcinogenesis. First, androgens induce prostate carcinogenesis in rodent models (R.L. Noble, Cancer Res 37, 1929-1933 (1977); R.L. Noble, Oncology 34, 138-141 (1977)), and men receiving androgens in the form of anabolic steroids have a higher incidence of prostate cancer (J.T. Roberts & D.M. Essenhigh, Lancet 2, 742 (1986); J.A. Jackson, J. Waxman & A.M. Spiekerman, Arch Intern Med 149, 2365-2366 (1989); P.D. Guinan, W. Sadoughi, H. Alsheik, R.J.Ablin, D. Alrenga & I.M. Bush, Am J Surg 131, 599-600 (1976)). Second, prostate cancer does not occur if humans or dogs are neutered before puberty (JD Wilson & C. Roehrborn, J Clin Endocrinol Metab 84, 4324-4331 (1999); G. Wilding, Cancer Surv 14, 113-130 (1992)).Castration in adult men causes prostate involution and prostate epithelial apoptosis without affecting other male external genitalia (E.M. Bruckheimer & N. Kyprianou, Cell Tissue Res 301, 153-162 (2000); J.T. Isaacs, Prostate 5, 545-557 (1984)). This dependence on androgens provides the basis for treating prostate cancer by chemical or surgical castration (androgen deprivation), also known as androgen deprivation therapy (ABT) or androgen deprivation therapy (ADT).
[0004] Androgens are also involved in female diseases such as polycystic ovary syndrome as well as cancer, one example of which is ovarian cancer, where elevated androgen levels are associated with an increased risk of developing ovarian cancer (KJ Helzlsouer, AJ Alberg, GB Gordon, C. Longcope, T.L. Bush, SCHoffman & G.W. Comstock, JAMA 274, 1926-1930 (1995); RJ Edmondson, JM Monaghan & B.R. Davies, Br J Cancer 86, 879-885 (2002)). AR has been detected in the majority of ovarian cancers (HA Risch, J Natl Cancer Inst 90, 1774-1786 (1998); BR Rao & B.J. Slotman, Endocr Rev 12, 14-26 (1991); GMClinton & W. Hua, Crit Rev Oncol Hematol 25, 1-9 (1997)), whereas estrogen receptor-alpha (ERa) and progesterone receptor are detected in less than 50% of ovarian tumors.
[0005] The only effective treatment available for advanced prostate cancer is the removal of androgens, which are essential for the survival of prostate luminal cells. Androgen deprivation therapy induces a temporary reduction in tumor burden accompanied by a decline in serum prostate-specific antigen (PSA). Unfortunately, prostate cancer can eventually regrow in the absence of testicular androgens (castration-resistant disease) (Huber et al. 1987 Scand J. Urol Nephrol. 104, 33-39). Castration-resistant prostate cancer, still driven by AR, is biochemically characterized by an increase in serum PSA levels prior to the onset of symptoms (Miller et al. 1992 J. Urol. 147, 956-961). Once the disease becomes castration-resistant, most patients die from the disease within two years.
[0006] The AR has distinct functional domains, including a carboxy-terminal ligand-binding domain (LBD), a DNA-binding domain (DBD) containing two zinc finger motifs, and an N-terminal domain (NTD) containing two transcriptional activation units (tau1 and tau5) within activation function-1 (AF-1). Binding of androgen (ligand) to the LBD of the AR results in its activation, allowing the receptor to efficiently bind to its specific DNA consensus sites, termed androgen response elements (AREs), on the promoter and enhancer regions of genes "normally" regulated by androgen, such as PSA, and initiate transcription. The AR can be activated by stimulation of the cAMP-dependent protein kinase (PKA) pathway, by interleukin-6 (IL-6), and by various growth factors, even in the absence of androgens (Culig et al. 1994 Cancer Res. 54, 5474-5478; Nazareth et al. 1996 J. Biol. Chem. 271, 19900-19907; Sadar 1999 J. Biol. Chem. 274, 7777-7783; Ueda et al. 2002 A J. Biol. Chem. 277, 7076-7085; and Ueda et al. 2002 B J. Biol. Chem. 277, 38087-38094). The mechanism of ligand-independent changes in AR has been shown to involve 1) an increase in nuclear AR protein, suggesting nuclear translocation, 2) increased AR / ARE complex formation, and 3) AR-NTD (Sadar 1999 J.Biol.Chem.274,7777-7783; Ueda et al. 2002 A J.Biol.Chem.277,7076-7085; and Ueda et al. 2002 B J.Biol.Chem.277,38087-38094). AR may be activated by alternative signaling pathways in castration-resistant disease, even in the absence of testicular androgens, consistent with the finding that nuclear AR protein is present in secondary prostate cancer tumors (Kim et al 2002 Am. J. Pathol. 160, 219-226, and van der Kwast et al 1991 Inter. J. Cancer 48, 189-193).
[0007] Clinically available AR inhibitors include non-steroidal antiandrogens, such as apalutamide, darolutamide, bicalutamide (Casodex®), nilutamide, flutamide, and enzalutamide. There are also steroidal antiandrogens, such as cyproterone acetate and spironolactone. Both steroidal and non-steroidal antiandrogens target the LBD of AR, but most do not work, likely due to low affinity and mutations that cause AR activation by these same antiandrogens (Taplin, ME, Bubley, GJ, Kom YJ, Small EJ, Upton M., Rajeshkumarm B., Balkm SP, Cancer Res., 59, 2511-2515 (1999)), as well as constitutively activated AR splice variants. Antiandrogens have no effect on the constitutively activated AR splice variant, which lacks the ligand-binding domain (LBD) and is associated with castration-recurrent prostate cancer (Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Cancer Res 68, 5469-77, 2008; Guo Z, Yang X, Sun F, Jiang R, Linn DE, Chen H, Chen H, Kong X, Melamed J, Tepper CG, Kung HJ, Brodie AM, Edwards J, Qiu Y. Cancer Res. 69, 2305-13, 2009; Hu et al. 2009 Cancer Res. 69, 16-22; Sun et al. 2010 J Clin Invest. 2010 120,2715-30), and is resistant to abiraterone and enzalutamide (Antonarakis et al., N Engl J Med. 2014,371,1028-38; Scher et al JAMA Oncol. 2016 doi:10.1001). Conventional therapies have focused on androgen-dependent activation of AR via its C-terminal domain.
[0008] Other related AR antagonists reported to date (see WO2010 / 000066, WO2011 / 082487, WO2011 / 082488, WO2012 / 145330, WO2015 / 031984, WO2016 / 058080, and WO2016 / 058082) that bind to full-length AR and / or truncated AR splice variants have recently been developed or are currently in development, including AR degraders such as niclosamide (Liu C et al 2014), galeterone (Njar et al 2015, Yu Z at al 2014), and ARV-330 / androgen receptor PROTAC (Neklesa et al 2016 J Clin Oncol 34 suppl 2S, abstr 267). The DBD inhibitor VPC-14449 (Dalal K et al 2014 J Biol Chem.289(38):26417-29, Li H et al 2014 J Med Chem.57(15):6458-67), the antiandrogen apalutamide (Clegg NJ et al 2012), ODM-201 (Moilanen AM et al 2015), ODM-204 (Kallio et al J Clin Oncol 2016 vol.34 no.2_suppl 230), TAS3681 (Minamiguchi et al 2015 J Clin Oncol 33,suppl 7, abstr 266), and the AR NTD inhibitors 3E10-AR441bsAb (Goicochea NL et al 2015) and sintokamide (Sadar et al 2008, Banuelos et al. 2016).
[0009] The AR-NTD is also a target for drug development (e.g., WO2000 / 001813, Myung et al. J. Clin. Invest 2013, 123, 2948) because the NTD contains the activation function-1 (AF-1), an essential region required for AR transcriptional activity (Jenster et al. 1991. Mol Endocrinol. 5, 1396-404). The AR-NTD plays a key role in AR activation, even in the absence of androgen (Sadar, MD 1999 J. Biol. Chem. 274, 7777-7783; Sadar MD et al 1999 Endocr Relat Cancer. 6, 487-502; Ueda et al 2002 J. Biol. Chem. 277, 7076-7085; Ueda 2002 J. Biol. Chem. 277, 38087-38094; Blaszczyk et al 2004 Clin Cancer Res. 10, 1860-9; Dehm et al 2006 J. Biol Chem. 28, 27882-93; Gregory et al 2004 J. Biol Chem. 279, 7119-30). The AR-NTD is important for hormone-driven prostate cancer progression, as shown by the application of decoy molecules (Quayle et al 2007, Proc Natl Acad Sci U S A. 104, 1331-1336).
[0010] While the crystal structure of the C-terminal LBD of AR has been solved, the NTD has not been analyzed due to its high flexibility and inherent disorder in solution (Reid et al. 2002 J. Biol. Chem. 277, 20079-20086), which has hindered virtual docking drug discovery approaches. Compounds that may modulate AR through interactions with the NTD domain have been published in PCT applications WO2010 / 000066, WO2011 / 082487, WO2011 / 082488, WO2012 / 145330, WO2012 / 139039, WO2012 / 145328, WO2013 / 028572, WO2013 / 028791, and WO2014 / 179 867, WO2015 / 031984, WO2016 / 058080, WO2016 / 058082, WO2016 / 112455, WO2016 / 141458, WO2017 / 177307, WO2017 / 210771, and WO2018 / 045450, which are incorporated herein by reference in their entireties.
[0011] Transcriptionally active androgen receptors play a key role in CRPC despite reduced blood levels of androgens (Karantanos, T. et al Oncogene 2013, 32, 5501-5511; Harris, W.P. et al Nature Clinical Practice Urology, 2009, 6, 76-85).The mechanisms underlying ADT resistance include AR overexpression (Visakorpi, T. et al Nature Genetics 1995, 9, 401-406; Koivisto, P. et al Scandinavian Journal of Clinical and Laboratory Investigation Supplementum 1996, 226, 57-63), gain-of-function mutations in the AR LBD (Culig Z. et al Molecular Endocrinology 1993, 7, 1541-1550), intratumoral androgen synthesis (Cai, C. et al Cancer Research 2011, 71, 6503-6513), alterations in the expression and function of AR coactivators (Ueda, T. et al The Journal of Biological Chemistry 2002, 277, 38087-38094; Xu J. et al Nature Reviews Cancer 2009, 9, 615-630), and abnormalities in post-translational modification of AR (Gioeli D. et al Molecular and Cellular Endocrinology 2012,352,70-78, van der Steen T. et al International Journal of Molecular Sciences 2013,14,14833-14859), as well as the expression of AR splice variants (AR-Vs) lacking the ligand-binding domain (LBD) (Karantanos, T. et al Oncogene 2013,32,5501-5511, Andersen RJ et al Cancer Cell 2010,17,535-546, Myung JK et al The Journal of Clinical Investigation 2013,123,2948-2960, Sun S. et al The Journal of Clinical Investigation 2010,120,2715-2730).Antiandrogens such as bicalutamide and enzalutamide target the AR LBD but are completely ineffective against truncated, constitutively active AR-Vs such as AR-V7 (Li Y. et al. Cancer Research 2013, 73, 483-489). Expression of AR-V7 is associated with resistance to current hormonal therapies (Li Y. et al. Cancer Research 2013, 73, 483-489; Antonarakis E. Set al. The New England Journal of Medicine 2014, 371, 1028-1038).
[0012] Although significant progress has been made in this field, there remains a need for improved treatment of AR-mediated disorders, including prostate cancer, particularly metastatic castration-resistant prostate cancer. The development of compounds that interact uniquely with the AR NTD would offer patients alternative options and new hope. Summary of the Invention
[0013] The compounds of the present disclosure are androgen receptor modulators that may be useful in the treatment of various diseases and conditions, such as those disclosed herein. In one embodiment, the present disclosure provides compounds of formula (IIIA): [ka]
[0014] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0015] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0016] C is a 3- to 10-membered ring;
[0017] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 and
[0018] Y is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, -NR 7 - or -N(COCH3)-,
[0019] W is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0020] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0021] V is -CH2- and L is halogen, -NH2, -CHCl2, -CCl3, or -CF3; or
[0022] V is -CH2CH2- and L is halogen or -NH2;
[0023] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16, optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0024] R 3 But halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0025] R 5 and R 6are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0026] R 7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
[0027] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0028] R 8a and R 9a each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0029] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0030] R 16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl;
[0031] each m is independently 0, 1, or 2;
[0032] n1 and n2 are each independently 0, 1, or 2;
[0033] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0034] R 16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl;
[0035] each m is independently 0, 1, or 2;
[0036] n1 and n2 are each independently 0, 1, or 2;
[0037] n3 is 1, 2, 3, 4 or 5;
[0038] t is 0, 1, or 2.
[0039] In one embodiment, the present disclosure provides a compound of formula (IVA): [ka]
[0040] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0041] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0042] C is a 3- to 10-membered ring;
[0043] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0044] Y and Z are each independently a bond, —CH—, —C(CH)H—, —O—, —S—, —NH—, —NCH—, or —N(COCH)—;
[0045] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0046] V is -CH2- and L is halogen, -NH2, or -CF3; or
[0047] V is -CH2CH2- and L is halogen or -NH2;
[0048] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16, optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0049] R 3 But halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0050] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0051] R 7 is H or C1-C6 alkyl,
[0052] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0053] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0054] n1 and n2 are each independently 0, 1, or 2;
[0055] n3 is 1, 2, 3, 4 or 5;
[0056] t is 0, 1, or 2.
[0057] In one embodiment of the compound of formula (IVA), C is a 5-10 membered heteroaryl or aryl. In some embodiments, C is a 5-7 membered heteroaryl containing 1, 2, or 3 heteroatoms selected from O, S, or N as ring members ... 3In some embodiments, C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan, or pyrimidyl, substituted with (R 3 )n3, [ka] [ka] wherein R 3a is C1-C3 alkyl.
[0058] In one embodiment of the compound of Formula (IVA), R 1 and R 2 are each independently Cl, —CN, —CF 3 , —OH, methyl, methoxy, or —CONH 2 .
[0059] In one embodiment of the compound of formula (IVA),
[0060] A and B are phenyl;
[0061] X is -(CR 5 R 6 ) t - and
[0062] Y and Z are each —O—;
[0063] V is -CH2- or -CH2CH2-,
[0064] L is a halogen;
[0065] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF, —OH, or optionally substituted C-C alkyl;
[0066] R 5 and R6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
[0067] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl.
[0068] In one embodiment of the compound of formula (IVA),
[0069] A and B are phenyl;
[0070] X is -(CR 5 R 6 ) t - and
[0071] W is -CH2- or -C(CH3)H-;
[0072] Y and Z are each —O—;
[0073] V is -CH2CH2-,
[0074] L is a halogen;
[0075] R 1 and R 2 are each independently hydrogen, halogen, or —CN;
[0076] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0077] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl.
[0078] In one embodiment, the present disclosure provides a compound of formula (AI): [ka]
[0079] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0080] C is phenyl or a 5- to 7-membered monocyclic heteroaryl containing 1, 2, or 3 heteroatoms selected from O, S, or N as ring members;
[0081] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0082] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0083] Z is a bond, —CH—, —O—, or —NH—;
[0084] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0085] V is -CH2- and L is halogen, -NH2, or -CF3; or
[0086] V is -CH2CH2- and L is halogen or -NH2;
[0087] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0088] R 3is -CN, C1-C3 alkoxy, -CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0089] R 5 and R 6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
[0090] R 7 is H or C1-C6 alkyl,
[0091] n1 and n2 are each independently 0, 1, or 2;
[0092] n3 is 1, 2, 3, 4 or 5;
[0093] t is 0, 1, or 2.
[0094] In one embodiment of the compound of formula (IVA),
[0095] In one embodiment of the compound of formula (AI), at least one R 3 is selected from -CN, C1-C3 alkoxy, -CONH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, or -SO2CH3, and other R 3When present, -CN, -CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H It is selected from —CO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
[0096] In one embodiment of the compound of formula (AI),
[0097] X is a bond or -(CR 5 R 6 ) t and
[0098] W is a bond, —CH—, or —C(CH)H—;
[0099] Y is —O—;
[0100] Z is -O-;
[0101] V is -CH2- or -CH2CH2-,
[0102] L is a halogen.
[0103] In one embodiment, the present disclosure provides a compound of formula (G-II): [ka]
[0104] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0105] C is, [ka] and
[0106] X is -(CR 5 R 6 ) t - and
[0107] Y is —O—;
[0108] Z is -O-;
[0109] W is -CH2- or -C(CH3)H-;
[0110] V is -CH2CH2-,
[0111] L is a halogen;
[0112] R 1 and R 2 are each independently Cl or —CN;
[0113] At least one R 3 is selected from -CN, C1-C3 alkoxy, -CONH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, or -SO2CH3, and other R 3When present, -CN, -CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0114] R 5 and R 6 are each independently hydrogen or methyl;
[0115] n1 and n2 are each independently 0, 1, or 2;
[0116] n3 is 1 or 2,
[0117] t is 1.
[0118] In one embodiment of the compound of Formula (G-II), at least one R 3 is selected from -NHSO2CH3, -NHSO2CH2CH3, or -SO2CH3, and other R 3 When present, -CN, C1-C3 alkyl, C1-C3 alkoxy, -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -SO2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 )COO(C1-C3 alkyl), -N H It is selected from —CO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
[0119] In one embodiment, the disclosure provides compounds A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the disclosure provides compounds A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and / or A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.
[0120] In one embodiment, the present disclosure provides a pharmaceutical composition comprising any one of the compounds of formula (IIIA), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the present disclosure provides a pharmaceutical composition comprising any one of the compounds of formula (IVA), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the present disclosure provides a pharmaceutical composition comprising any one of the compounds of formula (AI), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the present disclosure provides a pharmaceutical composition comprising any one of the compounds of formula (G-II), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier.
[0121] In one embodiment, the present disclosure provides a pharmaceutical composition comprising any one of compounds A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier. In one embodiment, the disclosure provides a pharmaceutical composition comprising any one of compounds A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, and a pharmaceutically acceptable carrier.
[0122] In one embodiment, the disclosure provides a method of treating cancer, the method comprising administering a compound of Formula (IIIA), (IVA), (AI), or (G-II), and any one of compounds A1-A96, A98-A116, A118-A159, A161-A175, or A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, to a subject in need thereof. In one embodiment, the cancer is prostate cancer. In one embodiment, the prostate cancer is metastatic castration-resistant prostate cancer. In other embodiments, the prostate cancer expresses a full-length androgen receptor or a truncated androgen receptor splice variant.
[0123] In one embodiment, the disclosure provides a method of treating cancer, the method comprising administering any one of compounds A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. [Brief explanation of the drawings]
[0124]
Figure 1
Figure 2A
Figure 2B
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
[0125] All publications, patents, and patent applications in this specification, including any drawings and exhibits, are incorporated by reference in their entirety for all purposes to the same extent as if each individual publication, patent or patent application, drawing, or exhibit was specifically and individually indicated to be incorporated by reference in its entirety for all purposes.
[0126] definition Although the following terms are believed to be well understood by those of ordinary skill in the art, the following definitions are provided to facilitate description of the subject matter disclosed herein.
[0127] Throughout this specification, the terms "about" and / or "approximately" may be used in connection with numerical values and / or ranges. The term "about" is understood to mean those values that are close to the recited value. Additionally, the phrases "less than about [value]" or "greater than about [value]" should be understood in light of the definition of the term "about" provided herein. The terms "about" and "approximately" may be used interchangeably.
[0128] Throughout this specification, numerical ranges are provided for certain quantities. These ranges should be understood to include all subranges thereof. Thus, a range such as "50 to 80" includes all possible ranges thereof (e.g., 51 to 79, 52 to 78, 53 to 77, 54 to 76, 55 to 75, 60 to 70, etc.). Furthermore, all values within a given range may be endpoints of the ranges encompassed therein (e.g., a range of 50 to 80 includes ranges with endpoints such as 55 to 80, 50 to 75, etc.).
[0129] The term "a" or "an" refers to one or more of that entity; for example, "an androgen receptor modulator" refers to one or more androgen receptor modulators or at least one androgen receptor modulator. Thus, the terms "a" (or "an"), "one or more," and "at least one" are used interchangeably herein. Additionally, reference to an "inhibitor" by the indefinite article "a" or "an" does not exclude the possibility that there is more than one inhibitor, unless the context clearly requires that there be only one inhibitor.
[0130] As used herein, the verb "comprise" and its conjugations as used in the description and claims are used in their open-ended sense, meaning that the items following the word are included, but items not specifically mentioned are not excluded. The present invention may suitably "comprise," "consist of," or "consist essentially of" the steps, elements, and / or reagents recited in the claims.
[0131] It should be further noted that the claims may be drafted to exclude any optional element. Accordingly, this statement is intended to serve as a predicate for the use of exclusive terminology such as "solely," "only," and the like, or the use of a "negative" limitation in connection with the recitation of claim elements.
[0132] The term "pharmaceutically acceptable salts" includes both acid addition salts and base addition salts. Pharmaceutically acceptable salts include those obtained by reacting an active compound that functions as a base with an inorganic or organic acid to form a salt, such as salts of hydrochloric acid, sulfuric acid, phosphoric acid, methanesulfonic acid, camphorsulfonic acid, oxalic acid, maleic acid, succinic acid, citric acid, formic acid, hydrobromic acid, benzoic acid, tartaric acid, fumaric acid, salicylic acid, mandelic acid, carbonic acid, and the like. Those skilled in the art will further recognize that acid addition salts may be prepared by reacting a compound with the appropriate inorganic or organic acid by any of a number of known methods.
[0133] The term "treat" refers to one or more of alleviating, ameliorating, delaying, reducing, ameliorating, or managing at least one symptom of a condition in a subject. The term "treat" can also refer to one or more of halting, delaying the onset (i.e., the period before clinical symptoms of a condition), or reducing the risk of developing or worsening a condition.
[0134] The compounds of the present invention, or pharmaceutically acceptable salts thereof, may contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that can be defined in terms of absolute stereochemistry as (R)- or (S)-, or for amino acids as (D)- or (L)-. The present disclosure is meant to encompass all such possible isomers, as well as their racemic and optically pure forms, whether or not they are specifically depicted herein. Optically active (+)- and (−), (R)- and (S)-, or (D)- and (L)-isomers can be prepared using chiral synthons or chiral reagents or resolved using conventional techniques, such as chromatography and fractional crystallization. Conventional techniques for the preparation / isolation of individual enantiomers include chiral synthesis from suitable optically pure precursors or resolution of the racemate (or racemate of a salt or derivative) using, for example, chiral high-pressure liquid chromatography (HPLC). When compounds described herein contain olefinic double bonds or other centers of geometric asymmetry, unless otherwise specified, the compounds are intended to include both E and Z geometric isomers, as well as all tautomeric forms.
[0135] "Stereoisomers" refer to compounds composed of the same atoms joined by the same bonds, but with different three-dimensional structures, and are not interchangeable. The present disclosure contemplates various stereoisomers and mixtures thereof, and includes "enantiomers," which refer to two stereoisomers whose molecules are non-superimposable mirror images of one another.
[0136] "Tautomer" refers to a proton migration from one atom of a molecule to another atom of the same molecule. The present disclosure includes tautomers of any compound.
[0137] "Prodrug" refers to a derivative of a compound of the present disclosure that will be converted to the compound in vivo. In one embodiment of the present disclosure, prodrugs include compounds of formula (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (V), (VA), (VI), (A), (AI), (B)-(D), (E), (EI)-(E-VII), (F), (G), (GI), (G-II), (H), and (HI) that have a free hydroxyl group (-OH) that is acetylated (-OCOMe) at one or more positions.
[0138] An "effective amount" means the amount of a formulation according to the invention that, when administered to a patient for treating a state, disorder or condition, is sufficient to effect such treatment. The "effective amount" will vary depending on the active ingredient, the state, disorder or condition to be treated and its severity, and the age, weight, physical condition and responsiveness of the mammal to be treated.
[0139] The term "therapeutically effective" as applied to a dose or amount refers to that amount of a compound or pharmaceutical preparation sufficient to result in a desired clinical benefit after administration to a patient in need thereof.
[0140] As used herein, a "subject" may be a human, non-human primate, mammal, rat, mouse, cow, horse, pig, sheep, goat, dog, cat, etc. The subject may be suspected of having or at risk of having cancer, such as prostate cancer, breast cancer, ovarian cancer, salivary gland cancer, or endometrial cancer, or may be suspected of having or at risk of having acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovarian disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration. Methods for diagnosing various cancers, such as prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, salivary gland cancer, or endometrial cancer, and methods for diagnosing and clinical manifestations of acne, hirsutism, alopecia, benign prostatic hyperplasia, ovarian cysts, polycystic ovarian disease, precocious puberty, spinal and bulbar muscular atrophy, or age-related macular degeneration, are known to those skilled in the art.
[0141] "Mammal" includes both humans and domestic animals, such as laboratory animals (e.g., mice, rats, monkeys, dogs, etc.) and household pets (e.g., cats, dogs, pigs, cows, sheep, goats, horses, rabbits), and non-domestic animals, such as wild animals.
[0142] All weight percentages (ie, "% by weight" and "wt.%" and w / w) referred to herein are measured relative to the total weight of the pharmaceutical composition, unless otherwise indicated.
[0143] As used herein, "substantially" or "substantially" refers to the complete or nearly complete extent or degree of an action, characteristic, property, state, structure, item, or result. For example, an object that is "substantially" enclosed would mean that the object is either completely enclosed or nearly completely enclosed. The precise tolerance for deviation from absolute completeness may depend in some cases on the specific context. Generally speaking, however, the proximity to completeness would result in the same overall result as would be obtained if absolute and complete completeness were obtained. The use of "substantially" is equally applicable when used in a negative connotation, referring to the complete or nearly complete absence of an action, characteristic, property, state, structure, item, or result. For example, a composition that is "substantially free" of other active agents would either be completely devoid of the other active agents or nearly completely devoid of the other active agents, such that the effect is the same as if the other active agents were completely absent. In other words, a composition that is "substantially free" of a component or element or another active agent may still contain such an item as long as there is no measurable effect of that item.
[0144] The following terms, as used herein, have the following meanings unless otherwise indicated:
[0145] "Amino" refers to the -NH2 radical.
[0146] "Cyano" refers to the -CN radical.
[0147] "Halo" or "halogen" refers to a bromo, chloro, fluoro, or iodo radical, including radioactive isotopes thereof. 123 "I" refers to the radioactive isotope of iodine having atomic mass 123. Compounds of formula I contain at least one 123 Throughout this application, structures may include a I moiety. 123 If an I part is shown, this means that the I part at this position 123I. In other words, the compound has greater than natural abundance at the indicated position(s). 123 The compound contains 100% I at the indicated position. 123 It does not have to include I, but 123 I is present above natural abundance. 123 The I isotope is 127 It is enriched by more than 50%, more than 60%, more than 70%, more than 80%, or more than 90% compared to I. 18 "F" refers to the radioactive isotope of fluorine with atomic mass 18. "F" or " 19 "F" refers to the abundant non-radioactive fluorine isotope having atomic mass 19. Compounds of formula I contain at least one 18 Throughout this application, structures may include F moieties at certain positions. 18 If an F moiety is shown, this means that the F moiety at this position 18 In other words, the compound has greater than natural abundance at the indicated position(s). 18 The compound contains 100% F at the position shown. 18 It does not have to contain F, but 18 F is present above natural abundance. 18 The F isotope is 19 are enriched by more than 50%, more than 60%, more than 70%, more than 80%, or more than 90% compared to F.
[0148] "Hydroxy" or "hydroxyl" refers to the --OH radical.
[0149] "Imino" refers to the =NH substituent.
[0150] "Nitro" refers to the -NO2 radical.
[0151] "Oxo" refers to the =O substituent.
[0152] "Thioxo" refers to the =S substituent.
[0153] "Alkyl" or "alkyl group" refers to a fully saturated straight or branched hydrocarbon chain radical having from 1 to 12 carbon atoms, which is attached to the rest of the molecule by a single bond. Alkyl containing any number of carbon atoms from 1 to 12 is included. Alkyl containing up to 12 carbon atoms is C1-C 12 Alkyl, containing up to 10 carbon atoms, is C1-C 10 An alkyl having up to 6 carbon atoms is a C1-C6 alkyl, and an alkyl having up to 5 carbon atoms is a C1-C5 alkyl. C1-C5 alkyl includes C5 alkyl, C4 alkyl, C3 alkyl, C2 alkyl, and C1 alkyl (i.e., methyl). C1-C6 alkyl includes all of the moieties described above for C1-C5 alkyl, and also includes C6 alkyl. C1-C 10 Alkyl includes all of the moieties described above for C1-C5 alkyl and C1-C6 alkyl, and also includes C7, C8, C9 and C 10 Also includes alkyl. Similarly, C1-C 12 Alkyl includes all of the above moieties, but also includes C 11 and C 12 Including alkyl. C1~C 12 Non-limiting examples of alkyl include methyl, ethyl, n-propyl, i-propyl, sec-propyl, n-butyl, i-butyl, sec-butyl, t-butyl, n-pentyl, t-amyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, n-decyl, n-undecyl, and n-dodecyl. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
[0154] "Alkylene" or "alkylene chain" refers to a fully saturated straight or branched divalent hydrocarbon chain radical having 1 to 12 carbon atoms. 12Non-limiting examples of alkylene include methylene, ethylene, propylene, n-butylene, ethenylene, propenylene, n-butenylene, propynylene, n-butynylene, etc. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain can be optionally substituted.
[0155] "Alkenyl" or "alkenyl group" refers to a straight or branched hydrocarbon chain radical having 2 to 12 carbon atoms and having one or more carbon-carbon double bonds. Each alkenyl group is attached to the rest of the molecule by a single bond. Alkenyl groups containing any number of carbon atoms from 2 to 12 are included. Alkenyl groups containing up to 12 carbon atoms are C2-C 12 Alkenyl, containing up to 10 carbon atoms, is C2-C 10 An alkenyl group containing up to 6 carbon atoms is C2-C6 alkenyl, and an alkenyl containing up to 5 carbon atoms is C2-C5 alkenyl. C2-C5 alkenyl includes C5 alkenyl, C4 alkenyl, C3 alkenyl, and C2 alkenyl. C2-C6 alkenyl includes all of the moieties described above for C2-C5 alkenyl, and also includes C6 alkenyl. C2-C 10 Alkenyl includes all of the moieties described above for C2-C5 alkenyl and C2-C6 alkenyl, and also includes C7, C8, C9 and C 10 Alkenyl is also included. Similarly, C2-C 12 Alkenyl includes all of the above moieties, but also includes C 11 and C 12 Includes alkenyl. C2-C 12Non-limiting examples of alkenyl include ethenyl (vinyl), 1-propenyl, 2-propenyl (allyl), iso-propenyl, 2-methyl-1-propenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-heptenyl, 2-heptenyl, 3-heptenyl, 4-heptenyl, 5-heptenyl, 6-heptenyl, 1-octenyl, 2-octenyl, 3-octenyl, 4-octenyl, 5-octenyl, 6-octenyl, 7-octenyl, 1-nonenyl, 2-nonenyl, and 3-nonenyl. , 4-nonenyl, 5-nonenyl, 6-nonenyl, 7-nonenyl, 8-nonenyl, 1-decenyl, 2-decenyl, 3-decenyl, 4-decenyl, 5-decenyl, 6-decenyl, 7-decenyl, 8-decenyl, 9-decenyl, 1-undecenyl, 2-undecenyl, 3-undecenyl, 4-undecenyl, 5-undecenyl, 6-undecenyl, 7-undecenyl, 8-undecenyl, 9-undecenyl, 10-undecenyl, 1-dodecenyl, 2-dodecenyl, 3-dodecenyl, 4-dodecenyl, 5-dodecenyl, 6-dodecenyl, 7-dodecenyl, 8-dodecenyl, 9-dodecenyl, 10-dodecenyl, and 11-dodecenyl. Unless stated otherwise specifically in the specification, an alkyl group may be optionally substituted.
[0156] "Alkenylene" or "alkenylene chain" refers to a linear or branched divalent hydrocarbon chain radical having 2 to 12 carbon atoms and having one or more carbon-carbon double bonds. 12 Non-limiting examples of alkenylene include ethene, propene, butene, etc. The alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain can be optionally substituted.
[0157] "Alkynyl" or "alkynyl group" refers to a straight or branched hydrocarbon chain radical having from 2 to 12 carbon atoms and having one or more carbon-carbon triple bonds. Each alkynyl group is attached to the rest of the molecule by a single bond. Alkynyl groups containing any number of carbon atoms from 2 to 12 are included. Alkynyl groups containing up to 12 carbon atoms are C2-C 12 Alkynyl, containing up to 10 carbon atoms, is C2-C 10 An alkynyl group containing up to 6 carbon atoms is C2-C6 alkynyl, and an alkynyl containing up to 5 carbon atoms is C2-C5 alkynyl. C2-C5 alkynyl includes C5 alkynyl, C4 alkynyl, C3 alkynyl, and C2 alkynyl. C2-C6 alkynyl includes all of the moieties listed above for C2-C5 alkynyl, and also includes C6 alkynyl. C2-C 10 Alkynyl includes all of the moieties described above for C2-C5 alkynyl and C2-C6 alkynyl, as well as C7, C8, C9 and C 10 Alkynyl is also included. Similarly, C2-C 12 Alkynyl includes all of the above moieties, but also includes C 11 and C 12 Alkynyl is included. C2-C 12 Non-limiting examples of alkynyl include ethynyl, propynyl, butynyl, pentynyl, etc. Unless stated otherwise specifically in the specification, an alkyl group can be optionally substituted.
[0158] "Alkynylene" or "alkynylene chain" refers to a linear or branched divalent hydrocarbon chain radical having 2 to 12 carbon atoms and having one or more carbon-carbon triple bonds. 12Non-limiting examples of alkynylene include ethynylene, propargylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain can be optionally substituted.
[0159] "Alkoxy" is a group of formulas -OR a where R a is an alkyl, alkenyl, or alkynyl radical, as defined above, containing 1 to 12 carbon atoms. Unless stated otherwise specifically in the specification, an alkoxy group can be optionally substituted.
[0160] "Alkylamino" has the formula -NHR a or -NR a R a where each R a is independently an alkyl, alkenyl, or alkynyl radical, as defined above, containing 1 to 12 carbon atoms. Unless stated otherwise specifically in the specification, an alkylamino group can be optionally substituted.
[0161] "Alkylcarbonyl" is -C(=O)R a refers to the moiety, where R a is an alkyl, alkenyl, or alkynyl radical as defined above. A non-limiting example of an alkylcarbonyl is a methylcarbonyl ("acetal") moiety. Alkylcarbonyl groups may also be referred to as "Cw-Cz acyl," where w and z are R as defined above. a For example, "C1 to C 10 "Acyl" refers to an alkylcarbonyl group, as defined above, where R a However, C1~C as defined above 10 Alkyl, C1-C 10 Alkenyl, or C1-C 10Unless stated otherwise specifically in the specification, an alkylcarbonyl group may be optionally substituted.
[0162] "Aryl" refers to a hydrocarbon ring system radical containing hydrogen, 6 to 18 carbon atoms, and at least one aromatic ring. For purposes of the present invention, an aryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused or bridged ring systems. Aryl radicals include, but are not limited to, aryl radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. Unless otherwise specifically stated in this specification, the term "aryl" is intended to include aryl radicals that are optionally substituted.
[0163] An "aralkyl" or "arylalkyl" is a group of the formula -R b -R c where R b is an alkylene group as defined above, and R c is one or more aryl radicals, as defined above, e.g., benzyl, diphenylmethyl, etc. Unless stated otherwise specifically in the specification, an aralkyl group may be optionally substituted.
[0164] An "aralkenyl" or "arylalkenyl" is an alkyl group of the formula -R b -R c where R b is an alkenylene group as defined above, and R c is one or more aryl radicals, as defined above. Unless stated otherwise specifically in the specification, an aralkenyl group may be optionally substituted.
[0165] An "aralkynyl" or "arylalkynyl" is an aralkynyl group of the formula -Rb -R c where R b is an alkynylene group as defined above, and R c is one or more aryl radicals, as defined above. Unless stated otherwise specifically in the specification, an aralkynyl group may be optionally substituted.
[0166] "Carbocyclyl," "carbocyclic ring," or "carbocycle" refers to a ring structure in which each atom forming the ring is carbon. A carbocyclic ring can contain from 3 to 20 carbon atoms within the ring. Carbocyclic rings include aryl and cycloalkyl, cycloalkenyl, and cycloalkynyl, as defined herein. Unless otherwise specifically stated in the specification, a carbocyclyl group can be optionally substituted.
[0167] "Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic fully saturated hydrocarbon radical, consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, attached to the remainder of the molecule by a single bond. Monocyclic cycloalkyl radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyl radicals include, for example, adamantyl, norbornyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless stated otherwise specifically in the specification, cycloalkyl groups can be optionally substituted.
[0168] "Cycloalkenyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical, consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon double bonds, and may include fused or bridged ring systems having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, which are attached to the remainder of the molecule by a single bond. Monocyclic cycloalkenyl radicals include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclooctenyl, and the like. Polycyclic cycloalkenyl radicals include, for example, bicyclo[2.2.1]hept-2-enyl, and the like. Unless otherwise specifically stated in the specification, a cycloalkenyl group can be optionally substituted.
[0169] "Cycloalkynyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical, consisting solely of carbon and hydrogen atoms, having one or more carbon-carbon triple bonds, and may include fused or bridged ring systems having 3 to 20 carbon atoms, preferably 3 to 10 carbon atoms, which are attached to the remainder of the molecule by a single bond. Monocyclic cycloalkynyl radicals include, for example, cycloheptynyl, cyclooctynyl, and the like. Unless otherwise specifically stated in the specification, a cycloalkynyl group may be optionally substituted.
[0170] "Cycloalkylalkyl" refers to a group of the formula -R b -R d where R b is an alkylene, alkenylene, or alkynylene group as defined above, and R d is a cycloalkyl, cycloalkenyl, cycloalkynyl radical, as defined above. Unless stated otherwise specifically in the specification, a cycloalkylalkyl group may be optionally substituted.
[0171] "Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, such as, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, etc. Unless stated otherwise specifically in the specification, a haloalkyl group can be optionally substituted.
[0172] "Haloalkenyl" refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, such as, for example, 1-fluoropropenyl, 1,1-difluorobutenyl, etc. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
[0173] "Haloalkynyl" refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, such as, for example, 1-fluoropropynyl, 1-fluorobutynyl, etc. Unless stated otherwise specifically in the specification, a haloalkenyl group can be optionally substituted.
[0174] "Heterocyclyl," "heterocyclic ring," or "heterocycle" refers to a stable 3- to 20-membered non-aromatic, partially aromatic, or aromatic ring radical, consisting of 2 to 12 carbon atoms and 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur. A heterocyclyl or heterocyclic ring includes heteroaryl as defined below. Unless stated otherwise specifically in the specification, a heterocyclyl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused or bridged ring systems; the nitrogen, carbon, or sulfur atoms in the heterocyclyl radical can be optionally oxidized; the nitrogen atom can be optionally quaternized; and the heterocyclyl radical can be partially saturated or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, and 1,1-dioxo-thiomorpholinyl. Unless stated otherwise specifically in the specification, heterocyclyl groups may be optionally substituted.
[0175] "Heterocyclylalkyl" refers to a group of the formula -R b -R e where R b is an alkylene group as defined above, and R e is a heterocyclyl radical, as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkyl group may be optionally substituted.
[0176] "Heterocyclylalkenyl" refers to a group of the formula -R b -R ewhere R b is an alkenylene group as defined above, and R e is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkenyl group may be optionally substituted.
[0177] "Heterocyclylalkynyl" refers to a group of the formula -R b -R e where R b is an alkynylene group as defined above, and R e is a heterocyclyl radical as defined above. Unless stated otherwise specifically in the specification, a heterocycloalkylalkynyl group may be optionally substituted.
[0178] "N-heterocyclyl" refers to a heterocyclyl radical, as defined above, containing at least one nitrogen, and the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. Unless stated otherwise specifically in the specification, an N-heterocyclyl group can be optionally substituted.
[0179] "Heteroaryl" refers to a 5- to 20-membered ring system radical containing a hydrogen atom, 1 to 13 carbon atoms, 1 to 6 heteroatoms selected from the group consisting of nitrogen, oxygen, and sulfur, and at least one aromatic ring. For purposes of this invention, a heteroaryl radical can be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which can include fused or bridged ring systems, and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical can be optionally oxidized, and the nitrogen atom can be optionally quaternized. Examples include azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzoindolyl, benzodioxolyl, benzofuranyl, benzoxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophene), benzotriazolyl, benzo[4,6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophene, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, and indophenyl. linyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophene (i.e., thienyl). Unless stated otherwise specifically in the specification, a heteroaryl group may be optionally substituted.
[0180] "N-heteroaryl" refers to a heteroaryl radical, as defined above, containing at least one nitrogen, and the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. Unless stated otherwise specifically in the specification, an N-heteroaryl group can be optionally substituted.
[0181] "Heteroarylalkyl" refers to a group of the formula -R b -R f where R b is an alkylene chain as defined above, and R f is a heteroaryl radical, as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkyl group may be optionally substituted.
[0182] "Heteroarylalkenyl" refers to a group of the formula -R b -R f where R b is an alkenylene chain as defined above, and R f is a heteroaryl radical, as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkenyl group may be optionally substituted.
[0183] "Heteroarylalkynyl" refers to a group of the formula -R b -R f where R b is an alkynylene chain as defined above, and R f is a heteroaryl radical, as defined above. Unless stated otherwise specifically in the specification, a heteroarylalkynyl group may be optionally substituted.
[0184] "Ring" refers to a cyclic group that may be fully saturated, partially saturated, or fully unsaturated. The ring may be monocyclic, bicyclic, tricyclic, or tetracyclic. Unless otherwise specifically stated in the specification, the ring may be optionally substituted.
[0185] "Thioalkyl" has the formula -SR a where R a is an alkyl, alkenyl, or alkynyl radical, as defined above, containing 1 to 12 carbon atoms. Unless stated otherwise specifically in the specification, a thioalkyl group may be optionally substituted.
[0186] The term "substituted," as used herein, means any of the above groups (i.e., alkyl, alkylene, alkenyl, alkenylene, alkynyl, alkynylene, alkoxy, alkylamino, alkylcarbonyl, thioalkyl, aryl, aralkyl, carbocyclyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl and / or heteroarylalkyl) wherein at least one hydrogen atom is replaced with a non-hydrogen atom, such as, but not limited to, F, Cl, or the like. , Br, and I; oxygen atoms in groups such as hydroxyl, alkoxy, and ester groups; sulfur atoms in groups such as thiol, thioalkyl, sulfone, sulfonyl, and sulfoxide groups; nitrogen atoms in groups such as amine, amide, alkylamine, dialkylamine, arylamine, alkylarylamine, diarylamine, N-oxide, imide, and enamine; silicon atoms in groups such as trialkylsilyl, dialkylarylsilyl, alkyldiarylsilyl, and triarylsilyl groups; and other heteroatoms in various other groups.
[0187] "Substituted" also refers to any of the above groups in which one or more hydrogen atoms are replaced by a higher bond (e.g., a double or triple bond) to a heteroatom, such as oxygen in oxo, carbonyl, carboxyl, and ester groups, and nitrogen in groups such as imine, oxime, hydrazone, and nitrile. For example, "substituted" includes any of the above groups in which one or more hydrogen atoms are replaced by a higher bond (e.g., a double or triple bond) to a heteroatom, such as oxygen in oxo, carbonyl, carboxyl, and ester groups, and nitrogen in groups such as imine, oxime, hydrazone, and nitrile. g Rh , -NR g C(=O)R h , -NR g C(=O)NR g R h , -NR g C(=O)OR h , -NR g SO2R h , -OC(=O)NR g R h , -OR g , -SR g , -SOR g , -SO2R g , -OSO2R g , -SO2OR g , =NSO2R g , and -SO2NR g R h Also, "substituted" means any of the above groups in which one or more hydrogen atoms are replaced by -C(=O)R g , -C(=O)OR g , -C(=O)NR g R h , -CH2SO2R g , -CH2SO2NR g R h In the previous example, R g and R hare the same or different and independently are hydrogen, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, and / or heteroarylalkyl. Additionally, "substituted" refers to any of the above groups where one or more hydrogen atoms are replaced by a bond to an amino, cyano, hydroxyl, imino, nitro, oxo, thioxo, halo, alkyl, alkenyl, alkynyl, alkoxy, alkylamino, thioalkyl, aryl, aralkyl, cycloalkyl, cycloalkenyl, cycloalkynyl, cycloalkylalkyl, haloalkyl, haloalkenyl, haloalkynyl, heterocyclyl, N-heterocyclyl, heterocyclylalkyl, heteroaryl, N-heteroaryl, and / or heteroarylalkyl group. In addition, each of the aforementioned substituents may also be optionally substituted with one or more of the above substituents.
[0188] As used herein, [ka] The symbol (which may hereinafter be referred to as a "point bond") indicates a bond that is a point of attachment between two chemical entities, one of which is shown as being attached to the point bond and the other of which is not shown as being attached to the point bond. For example, [ka] indicates that the chemical entity "XY" is attached to another chemical entity via a point-of-attachment bond. Additionally, specific points of attachment to chemical entities not shown may be identified by inference. For example, the compound CH3-R 3 where R 3 is H or [ka] and R 3 If "XY" then R 3 It is assumed that the bond shown as connecting to CH3 and the point of attachment bond are the same bond.
[0189] "Fused" refers to any ring structure described herein that is fused to an existing ring structure in the compounds of the present invention. When the fused ring is a heterocyclyl ring or a heteroaryl ring, any carbon atom on the existing ring structure that becomes part of the fused heterocyclyl ring or fused heteroaryl ring can be replaced with a nitrogen atom.
[0190] The following description contains information that may be useful in understanding the present invention. No admission is made that any of the information provided herein is prior art or relevant to the presently claimed invention, or that any publication specifically or implicitly referenced is prior art.
[0191] Compounds of the Disclosure The compounds of the present disclosure can be useful for regulating androgen receptor (AR).In addition, the compounds of the present disclosure can be useful for treating various diseases and conditions, including but not limited to cancer.In some embodiments, cancer is prostate cancer or breast cancer.
[0192] In one embodiment, the present disclosure provides a compound of formula (I): [ka]
[0193] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0194] A and B are each independently aryl or heteroaryl;
[0195] C is a 3- to 10-membered ring;
[0196] X is a bond, -(CR 5 R 6 ) t -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, -NR 7 -, -N(R 7 )CO-, -CON(R 7 )-, or -NSO2R 7 - and
[0197] Y and Z each independently represent a bond, -(CR 8 R 9 ) m -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0198] W and V each independently represent a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0199] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0200] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0201] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16, -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0202] R 5 and R 6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 5 and R 6 together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0203] R 8 and R 9are each independently hydrogen, halogen, or C1-C3 alkyl;
[0204] R 8a and R 9a are each independently hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —OCO(C1-C6 alkyl), —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 8a and R 8b together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0205] R 7 , R 10 and R 16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 7 and R 8a together form an optionally substituted heterocyclyl;
[0206] R 11 , R12 , R 13 , R 14 and R 15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or (R 11 and R 12 ) or (R 14 and R 15 ) together form an optionally substituted heterocyclyl;
[0207] each m is independently 0, 1, or 2;
[0208] n1 and n2 are each independently 0, 1, 2, 3, or 4;
[0209] n3 is 0, 1, 2, 3, 4 or 5;
[0210] Each t is independently 0, 1, or 2.
[0211] In one embodiment, the present disclosure provides a compound of formula (IA): [ka]
[0212] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0213] A and B are each independently aryl or heteroaryl;
[0214] C is a 3- to 10-membered ring;
[0215] X is a bond, -(CR 5 R 6 ) t-, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, -NR 7 -, -N(R 7 )CO-, -CON(R 7 )-, or -NSO2R 7 - and
[0216] Y and Z each independently represent a bond, -(CR 8 R 9 ) m -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0217] W and V each independently represent a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0218] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0219] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0220] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COOR 16 , -NR 14 COR 16 , -NR 14 CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-NR 14 COR16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0221] R 5 and R 6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 5 and R 6 together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0222] R 8 and R 9are each independently hydrogen, halogen, or C1-C3 alkyl;
[0223] R 8a and R 9a are each independently hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted —OCO(C1-C6 alkyl), —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 8a and R 8b together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0224] R 7 , R 10 and R 16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO(optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R 7 and R 8atogether form an optionally substituted heterocyclyl;
[0225] R 11 , R 12 , R 13 , R 14 and R 15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or (R 11 and R 12 ) or (R 14 and R 15 ) together form an optionally substituted heterocyclyl;
[0226] each m is independently 0, 1, or 2;
[0227] n1 and n2 are each independently 0, 1, 2, 3, or 4;
[0228] n3 is 0, 1, 2, 3, 4 or 5;
[0229] Each t is independently 0, 1, or 2.
[0230] In one embodiment, the present disclosure provides a compound of formula (IB): [ka]
[0231] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0232] A and B are each independently aryl or heteroaryl;
[0233] C is a 3- to 10-membered ring;
[0234] X is a bond, -(CR 5 R 6 ) t -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, -NR 7 -, -N(R 7 )CO-, -CON(R 7 )-, or -NSO2R 7 - and
[0235] Y is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0236] W is a bond, -(CR 8a R 9a ) m -, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0237] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0238] V is -CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)-, or -CH2CH2CH2-;
[0239] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0240] R 1 and R 2each independently represents hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0241] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COOR 16 , -NR 14 COR 16 , -NR 14 CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0242] R 5 and R 6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 5 and R 6 together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0243] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0244] R 8a and R 9a each independently represents hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 8a and R 8b together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0245] R 7 , R 10 and R16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkyl-NH2, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO(optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R 7 and R 8a together form an optionally substituted heterocyclyl;
[0246] R 11 , R 12 , R 13 , R 14 and R 15 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or (R 11 and R 12 ) or (R 14 and R 15 ) or (R 14 and R 16 ) together form an optionally substituted heterocyclyl;
[0247] each m is independently 0, 1, or 2;
[0248] n1 and n2 are each independently 0, 1, 2, 3, or 4;
[0249] n3 is 0, 1, 2, 3, 4 or 5;
[0250] Each t is independently 0, 1, or 2.
[0251] In one embodiment, the present disclosure provides a compound of formula (IC) [ka]
[0252] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0253] A and B are each independently aryl or heteroaryl;
[0254] C is a 3- to 10-membered ring;
[0255] X is a bond, -(CR 5 R 6 ) t -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, -NR 7 -, -N(R 7 )CO-, -CON(R 7 )-, or -NSO2R 7 - and
[0256] Y is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0257] W is a bond, -(CR 8a R 9a ) m -, -C(=O)-, N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0258] Z is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0259] V is -CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)-, or -CH2CH2CH2-;
[0260] L is hydrogen, halogen, -CF2R 10 , -CF3, -CCl2R 10 , -CCl3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0261] R 1 and R 2 each independently represents hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0262] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COOR 16 , -NR 14 COR 16 , -NR 14 CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl;
[0263] R 5 and R 6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 5 and R 6 together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0264] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0265] R 8a and R 9a each independently represents hydrogen, —OH, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, —NR 13 R 14, optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 8a and R 8b together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl;
[0266] R 7 , R 10 and R 16 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkyl-NH2, C1-C6 haloalkyl, C2-C6 haloalkenyl, C2-C6 haloalkynyl, optionally substituted carbocyclyl, optionally substituted —CO(C1-C6 alkyl), —CO(optionally substituted heterocyclyl), optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl; or R 7 and R 8a together form an optionally substituted heterocyclyl;
[0267] R 11 , R 12 , R 13 , R 14 and R 15are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted —COO(C1-C6 alkyl), optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or (R 11 and R 12 ) or (R 14 and R 15 ) or (R 14 and R 16 ) together form an optionally substituted heterocyclyl;
[0268] each m is independently 0, 1, or 2;
[0269] n1 and n2 are each independently 0, 1, 2, 3, or 4;
[0270] n3 is 0, 1, 2, 3, 4 or 5;
[0271] Each t is independently 0, 1, or 2.
[0272] In one embodiment, the present disclosure provides a compound of formula (II): [ka]
[0273] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0274] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0275] C is a 3- to 10-membered ring;
[0276] X is a bond, -(CR 5 R 6 ) t-, or -NR 7 - and
[0277] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0278] Z is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0279] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -NHCO-, -N(C1-C3 alkyl)CO-, -CONH-, or -CON(C1-C3 alkyl)-;
[0280] V is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0281] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0282] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0283] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15, -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0284] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0285] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0286] R 8a and R 9a each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0287] R 11 , R 12 , R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R15 together form a 3- to 6-membered heterocyclyl,
[0288] R 7 , R 10 and R 16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
[0289] each m is independently 0, 1, or 2;
[0290] n1 and n2 are each independently 0, 1, or 2;
[0291] n3 is 0, 1, 2, 3, 4 or 5;
[0292] t is 0, 1, or 2.
[0293] In one embodiment, the present disclosure provides a compound of formula (IIA): [ka]
[0294] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0295] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0296] C is a 3- to 10-membered ring;
[0297] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0298] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0299] Z is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0300] W is a bond, -CH2-, -C(CH3)H-, -NHCO-, -N(C1-C3 alkyl)CO-, -CONH-, or -CON(C1-C3 alkyl)-;
[0301] V is -CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)-, or -CH2CH2CH2-;
[0302] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0303] R 1 and R 2 each independently represents hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14, optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0304] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0305] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0306] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0307] R 11 , R 12 , R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0308] R 7 , R 10 and R 16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkyl-NH2, or R 14 and R 16 together form a 3- to 6-membered heterocyclyl,
[0309] each m is independently 0, 1, or 2;
[0310] n1 and n2 are each independently 0, 1, or 2;
[0311] n3 is 0, 1, 2, 3, 4 or 5;
[0312] t is 0, 1, or 2.
[0313] In one embodiment, the present disclosure provides a compound of formula (IIB): [ka]
[0314] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0315] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0316] C is a 3- to 10-membered ring;
[0317] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0318] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0319] Z is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0320] W is a bond, —CH—, or —C(CH)H—;
[0321] V is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0322] L is hydrogen, halogen, -CF2R 10 , -CF3, -CN, -OR 10 , -NR 11 R 12 , or -CONR 11 R 12 and
[0323] R 1 and R2 each independently represents hydrogen, deuterium, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0324] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16, -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0325] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0326] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0327] R 8a and R 9a each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8btogether form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0328] R 11 , R 12 , R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0329] R 7 , R 10 and R 16 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, or C1-C6 alkyl-NH2, or R 14 and R 16 together form a 3- to 6-membered heterocyclyl,
[0330] each m is independently 0, 1, or 2;
[0331] n1 and n2 are each independently 0, 1, or 2;
[0332] n3 is 1, 2, 3, 4 or 5;
[0333] t is 0, 1, or 2.
[0334] In one embodiment, the present disclosure provides a compound of formula (III): [ka]
[0335] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0336] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0337] C is a 3- to 10-membered ring;
[0338] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0339] Y is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO2-, or -NR 7 - and
[0340] W is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0341] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0342] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0343] L is halogen, -NH2, or -CF3;
[0344] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0345] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15, -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0346] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0347] R 7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
[0348] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0349] R 8a and R 9a each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0350] R 13 , R 14 and R 15are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0351] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0352] each m is independently 0, 1, or 2;
[0353] n1 and n2 are each independently 0, 1, or 2;
[0354] n3 is 0, 1, 2, 3, 4 or 5;
[0355] t is 0, 1, or 2.
[0356] In one embodiment, the present disclosure provides a compound of formula (IIIA): [ka]
[0357] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0358] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0359] C is a 3- to 10-membered ring;
[0360] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 and
[0361] Y is a bond, -(CR 8 R 9 ) m-, -O-, -S-, -S(=O)-, -SO2-, -NR 7 - or -N(COCH3)-,
[0362] W is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 - and
[0363] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0364] V is -CH2- and L is halogen, -NH2, -CHCl2, -CCl3, or -CF3; or
[0365] V is -CH2CH2- and L is halogen or -NH2;
[0366] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14, optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0367] R 3 But halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0368] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0369] R 7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl;
[0370] R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl;
[0371] R 8a and R 9a each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0372] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0373] R 16is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl;
[0374] each m is independently 0, 1, or 2;
[0375] n1 and n2 are each independently 0, 1, or 2;
[0376] n3 is 1, 2, 3, 4 or 5;
[0377] t is 0, 1, or 2.
[0378] In one embodiment, the present disclosure provides a compound of formula (IV): [ka]
[0379] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0380] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0381] C is a 3- to 10-membered ring;
[0382] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0383] Y and Z are each independently a bond, —CH—, —C(CH)H—, —O—, —S—, —NH—, —NCH—, or —N(COCH)—;
[0384] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR7 - and
[0385] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0386] L is halogen, -NH2, or -CF3;
[0387] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0388] R 3 is hydrogen, halogen, oxo, =S, =NR 16, -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0389] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0390] R 7 is H or C1-C6 alkyl,
[0391] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0392] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0393] n1 and n2 are each independently 0, 1, or 2;
[0394] n3 is 0, 1, 2, 3, 4 or 5;
[0395] t is 0, 1, or 2.
[0396] In one embodiment, the present disclosure provides a compound of formula (V): [ka]
[0397] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0398] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0399] C is a 5- to 10-membered heteroaryl or aryl;
[0400] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0401] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0402] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0403] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0404] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0405] L is halogen, -NH2, or -CF3;
[0406] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0407] R 3is hydrogen, halogen, oxo, =S, -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0408] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0409] R 7 is H or C1-C6 alkyl,
[0410] R 13 , R 14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0411] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0412] n1 and n2 are each independently 0, 1, or 2;
[0413] n3 is 0, 1, 2, 3, 4 or 5;
[0414] t is 0, 1, or 2.
[0415] In one embodiment, the present disclosure provides a compound of formula (VA): [ka]
[0416] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0417] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0418] C is a 5- to 10-membered heteroaryl or aryl;
[0419] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 and
[0420] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0421] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0422] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0423] V is -CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)-, or -CH2CH2CH2-;
[0424] L is hydrogen, halogen, -OH, -NH2, or -CF3;
[0425] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0426] R 3 is hydrogen, halogen, oxo, =S, -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -NR 14 COOR 16 , -NR 14 CONR 14 R 15 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0427] R 5 and R 6 are each independently hydrogen, halogen, —OH, —NH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0428] R 7 is H, C1-C6 alkyl, or —CO(C1-C6 alkyl),
[0429] R 13 , R 14 and R15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or -COO(C1-C6 alkyl), or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0430] R 16 is hydrogen, C1-C3 alkyl, C1-C3 haloalkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0431] n1 and n2 are each independently 0, 1, or 2;
[0432] n3 is 0, 1, 2, 3, 4 or 5;
[0433] t is 0, 1, or 2.
[0434] In one embodiment, the present disclosure provides a compound of formula (VI): [ka]
[0435] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0436] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0437] C is a 5- to 10-membered heterocyclyl;
[0438] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0439] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0440] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0441] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0442] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0443] L is halogen, -NH2, or -CF3;
[0444] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0445] R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0446] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0447] R 7 is H or C1-C6 alkyl,
[0448] R 13 , R14 and R 15 are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0449] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0450] n1 and n2 are each independently 0, 1, or 2;
[0451] n3 is 0, 1, 2, 3, 4 or 5;
[0452] t is 0, 1, or 2.
[0453] In one embodiment, the present disclosure provides a compound of formula (A): [ka]
[0454] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0455] C is phenyl or a 5- to 7-membered monocyclic heteroaryl containing 1, 2, or 3 heteroatoms selected from O, S, or N as ring members;
[0456] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0457] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0458] Z is a bond, —CH—, —O—, or —NH—;
[0459] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0460] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0461] L is halogen, -NH2, or -CF3;
[0462] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0463] R 3 is selected from hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl);
[0464] R 5 and R 6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
[0465] R 7 is H or C1-C6 alkyl,
[0466] n1 and n2 are each independently 0, 1, or 2;
[0467] n3 is 0, 1, 2, 3, 4 or 5;
[0468] t is 0, 1, or 2.
[0469] In one embodiment, the present disclosure provides a compound of formula (B): [ka]
[0470] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0471] C is a 5- to 7-membered saturated or partially saturated monocyclic heterocycle containing 1, 2, or 3 heteroatoms selected from O, S, or N as ring members;
[0472] X is a bond, -(CR 5 R 6 ) t -, or -NR 7 - and
[0473] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0474] Z is a bond, —CH—, —O—, or —NH—;
[0475] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 - and
[0476] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0477] L is halogen, -NH2, or -CF3;
[0478] R 1 and R 2are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0479] R 3 Hydrogen, F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl);
[0480] R 5 and R 6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
[0481] R 7 is H or C1-C6 alkyl,
[0482] R 16 is hydrogen or C1-C3 alkyl,
[0483] n1 and n2 are each independently 0, 1, or 2;
[0484] n3 is 0, 1, 2, 3, 4 or 5;
[0485] t is 0, 1, or 2.
[0486] In one embodiment of a compound of Formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), -VL is -CH2CH2Cl, -CH2CH2CH2Cl, -CH2CH2NH2, or -CH2CH2CH2NH2.
[0487] In one embodiment of a compound of Formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), -YW- is a bond, -OCH2-, -OCH2CH2-, -OCH(CH3)-, -NH-, -NHCH2-, -NHC(=O)-, or -C(=O)NH-.
[0488] In one embodiment of a compound of Formula (I), (IC), (II), (III), (IIIA), (IV), (V), (VI), (A), or (B), X is a bond, —CH—, —C(CH)H—, —C(CH)—, or —CHCH—.
[0489] In one embodiment, the present disclosure provides a compound of formula (C): [ka]
[0490] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0491] A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene;
[0492] X is a bond, (CR 5 R 6 ) t -, or -NR 7 - and
[0493] Y is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0494] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0495] W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7)CO- or -CONR 7 - and
[0496] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0497] L is halogen, -NH2, or -CF3;
[0498] D is -NH or -NR 3 and
[0499] each U is independently O, S, or NR 16 and
[0500] R 1 and R 2 each independently represents hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 13 R 14 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16or optionally substituted -(C1-C6 alkyl)-SO2R 16 and
[0501] R 3 is hydrogen, halogen, -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl);
[0502] R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl;
[0503] R 7 is H or C1-C6 alkyl,
[0504] R 13 , R 14 and R 15are each independently hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl, or R 14 and R 15 together form a 3- to 6-membered heterocyclyl,
[0505] R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl;
[0506] n1 and n2 are each independently 0, 1, or 2;
[0507] n3 is 0, 1, 2, or 3;
[0508] t is 0, 1, or 2.
[0509] In one embodiment, the present disclosure provides a compound of formula (D): [ka]
[0510] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0511] C is a 5-6 membered heteroaryl containing 1 or 2 heteroatoms selected from O, S, or N as ring members;
[0512] X is -(CR 5 R 6 ) t -or-NR 7 - and
[0513] Y is a bond, —CH—, —O—, or —NH—;
[0514] Z is a bond, —CH—, —O—, or —NH—;
[0515] W is a bond, —CH—, or —C(CH)H—;
[0516] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0517] L is hydrogen, halogen, -NH2, or -CF3;
[0518] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0519] R 3 is selected from hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl);
[0520] R 5 and R 6 are each independently hydrogen, halogen, —OH, or C1-C3 alkyl;
[0521] R 7 is H or C1-C6 alkyl,
[0522] n1 and n2 are each independently 0, 1, or 2;
[0523] n3 is 0, 1, 2, 3, 4 or 5;
[0524] t is 0, 1, or 2.
[0525] In one embodiment, the present disclosure provides a compound of formula (E): [ka]
[0526] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0527] C is, [ka] and
[0528] X is -(CR 5 R 6 ) t -or-NR 7 - and
[0529] Y is a bond, —CH—, —O—, or —NH—;
[0530] Z is a bond, —CH—, —O—, or —NH—;
[0531] W is a bond, —CH—, or —C(CH)H—;
[0532] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0533] L is hydrogen or halogen;
[0534] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0535] R 3is selected from hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl);
[0536] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0537] R 7 is H or C1-C6 alkyl,
[0538] n1 and n2 are each independently 0, 1, or 2;
[0539] n3 is 0, 1, or 2;
[0540] t is 1 or 2.
[0541] In one embodiment, the present disclosure provides a compound of formula (EI): [ka]
[0542] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0543] C is, [ka] and
[0544] X is -(CR 5 R 6) t -or-NR 7 - and
[0545] Y is a bond, —CH—, —O—, or —NH—;
[0546] Z is a bond, —CH—, —O—, or —NH—;
[0547] W is a bond, —CH—, or —C(CH)H—;
[0548] V is -CH2-, -CH2CH2-, -CH2CH2CH2-, or -CH2CHClCH2-;
[0549] L is hydrogen, —OH, or halogen;
[0550] R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0551] R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0552] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0553] R 7 is H or C1-C6 alkyl,
[0554] n1 and n2 are each independently 0, 1, or 2;
[0555] n3 is 0, 1, or 2;
[0556] t is 1 or 2.
[0557] In one embodiment of the compounds of Formula (A)-(C) or (E-1), R 3 is selected from hydrogen, F, Cl, Br, I, -CN, -CF3, -OH, methyl, methoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -NHCO(C1-C3 alkyl).
[0558] In one embodiment, the present disclosure provides a compound of formula (F): [ka]
[0559] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0560] C is, [ka] and
[0561] X is -(CR 5 R 6 ) t -or-NR 7 - and
[0562] Y is —O—;
[0563] Z is -O-;
[0564] W is -CH2- or -C(CH3)H-;
[0565] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0566] L is hydrogen or halogen;
[0567] R 1 and R 2 are each independently halogen or —CN;
[0568] R 3 is selected from -NHSO2CH3, -N(CH3)SO2CH3, or -SO2CH3;
[0569] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0570] R 7 is H or C1-C6 alkyl,
[0571] n1 and n2 are each independently 0, 1, or 2;
[0572] n3 is 0, 1, or 2;
[0573] t is 1 or 2.
[0574] In one embodiment, the present disclosure provides a compound of formula (G): [ka]
[0575] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0576] C is, [ka]
[0577] X is -(CR 5 R 6 ) t -or-NR 7 - and
[0578] Y is —O—;
[0579] Z is -O-;
[0580] W is -CH2- or -C(CH3)H-;
[0581] V is -CH2- and L is hydrogen, or
[0582] or alternatively, V is —CH2CH2— or —CH2CH2CH2— and L is halogen;
[0583] R 1 and R 2 are each independently Cl or —CN;
[0584] R 3 is selected from -NHSO2CH3, -N(CH3)SO2CH3, or -SO2CH3;
[0585] R 5 and R 6 are each independently hydrogen or methyl;
[0586] R 7 is H or C1-C6 alkyl,
[0587] n1 and n2 are each independently 0, 1, or 2;
[0588] n3 is 1 or 2,
[0589] t is 1.
[0590] In one embodiment, the present disclosure provides a method for producing a compound comprising: (GI) [ka]
[0591] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0592] C is, [ka] and
[0593] X is -(CR 5 R 6 ) t - and
[0594] Y is —O—;
[0595] Z is -O-;
[0596] W is -CH2- or -C(CH3)H-;
[0597] V is -CH2CH2- or -CH2CH2CH2-,
[0598] L is a halogen;
[0599] R 1 and R 2 are each independently Cl or —CN;
[0600] R 3 is selected from -NHSO2CH3, -N(CH3)SO2CH3, or -SO2CH3;
[0601] R 5 and R 6 are each independently hydrogen or methyl;
[0602] n1 and n2 are each independently 0, 1, or 2;
[0603] n3 is 1 or 2,
[0604] t is 1.
[0605] In one embodiment, the present disclosure provides a compound of formula (G-II): [ka]
[0606] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0607] C is, [ka] and
[0608] X is -(CR 5 R 6 ) t - and
[0609] Y is —O—;
[0610] Z is -O-;
[0611] W is -CH2- or -C(CH3)H-;
[0612] V is -CH2CH2-,
[0613] L is a halogen;
[0614] R1 and R 2 are each independently Cl or —CN;
[0615] At least one R 3 is selected from -CN, C1-C3 alkoxy, -CONH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, or -SO2CH3, and other R 3 When present, -CN, -CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0616] R 5 and R 6 are each independently hydrogen or methyl;
[0617] n1 and n2 are each independently 0, 1, or 2;
[0618] n3 is 1 or 2,
[0619] t is 1.
[0620] In one embodiment, the present disclosure provides a compound of formula (H): [ka]
[0621] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0622] CI, [ka] and
[0623] X is -(CR 5 R 6 ) t -or-NR 7 - and
[0624] Y is —O—;
[0625] Z is -O-;
[0626] W is -CH2- or -C(CH3)H-;
[0627] V is -CH2-, -CH2CH2- or -CH2CH2CH2-;
[0628] L is a halogen;
[0629] R 1 and R 2 are each independently Cl or —CN;
[0630] R 5 and R 6 are each independently hydrogen or methyl;
[0631] R 7 is H or C1-C6 alkyl,
[0632] n1 and n2 are each independently 0, 1, or 2;
[0633] t is 1.
[0634] In one embodiment, the present disclosure provides a compound of formula (HI): [ka]
[0635] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0636] CI, [ka] and
[0637] X is -(CR 5 R 6 ) t - and
[0638] Y is —O—;
[0639] Z is -O-;
[0640] W is -CH2- or -C(CH3)H-;
[0641] V is -CH2-, -CH2CH2- or -CH2CH2CH2-;
[0642] L is a halogen;
[0643] R 1 and R 2 are each independently Cl or —CN;
[0644] R 5 and R 6 are each independently hydrogen or methyl;
[0645] R 7 is H or C1-C6 alkyl,
[0646] n1 and n2 are each independently 0, 1, or 2;
[0647] t is 1.
[0648] In one embodiment, the present disclosure provides a compound of formula (E-II): [ka]
[0649] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0650] C is, [ka] and
[0651] X is -(CR 5 R 6 )- and
[0652] Y is a bond, —CH—, —O—, or —NH—;
[0653] Z is a bond, —CH—, —O—, or —NH—;
[0654] W is a bond, —CH—, or —C(CH)H—;
[0655] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0656] L is a halogen;
[0657] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0658] R 3is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0659] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0660] n1 is 0, 1, or 2;
[0661] n3 is 1 or 2,
[0662] In the formula, CR 3 but [ka] If R 2A and R 2B are not Cl.
[0663] In one embodiment, the present disclosure provides a compound of formula (E-III): [ka]
[0664] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0665] C is, [ka] and
[0666] X is -(CR 5 R 6 )- and
[0667] Y is a bond, —CH—, —O—, or —NH—;
[0668] Z is a bond, —CH—, —O—, or —NH—;
[0669] W is a bond, —CH—, or —C(CH)H—;
[0670] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0671] L is a halogen;
[0672] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0673] R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H-CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0674] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0675] n1 is 0, 1, or 2;
[0676] n3 is 1 or 2,
[0677] In the formula, CR 3 but [ka] and R 2A and R 2B If one of R is Cl, 2A and R 2B The other is not -CN.
[0678] In one embodiment, the present disclosure provides a compound of formula (E-IV): [ka]
[0679] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0680] C is, [ka] and
[0681] X is -(CR 5 R 6 )- and
[0682] Y is a bond, —CH—, —O—, or —NH—;
[0683] Z is a bond, —CH—, —O—, or —NH—;
[0684] W is a bond, —CH—, or —C(CH)H—;
[0685] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0686] L is a halogen;
[0687] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0688] R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0689] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0690] n1 is 0, 1, or 2;
[0691] n3 is 1 or 2.
[0692] In one embodiment, the present disclosure provides a compound of formula (EV): [ka]
[0693] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0694] C is, [ka] and
[0695] X is -(CR 5 R 6 )- and
[0696] Y is a bond, —CH—, —O—, or —NH—;
[0697] Z is a bond, —CH—, —O—, or —NH—;
[0698] W is a bond, —CH—, or —C(CH)H—;
[0699] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0700] L is a halogen;
[0701] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0702] R 3is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0703] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0704] n1 is 0, 1, or 2;
[0705] n3 is 1 or 2,
[0706] In the formula, CR 3 but [ka] If R 2A and R 2B are not Cl.
[0707] In one embodiment, the present disclosure provides a compound of formula (E-VI): [ka]
[0708] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0709] C is, [ka] and
[0710] X is -(CR 5 R 6 )- and
[0711] Y is a bond, —CH—, —O—, or —NH—;
[0712] Z is a bond, —CH—, —O—, or —NH—;
[0713] W is a bond, —CH—, or —C(CH)H—;
[0714] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0715] L is a halogen;
[0716] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0717] R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H-CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0718] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0719] n1 is 0, 1, or 2;
[0720] n3 is 1 or 2,
[0721] In the formula, CR 3 but [ka] and R 2A and R 2B If one of R is Cl, 2A and R 2B The other is not -CN.
[0722] In one embodiment, the present disclosure provides a compound of formula (E-VII): [ka]
[0723] or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof, wherein:
[0724] C is, [ka] and
[0725] X is -(CR 5 R 6 )- and
[0726] Y is a bond, —CH—, —O—, or —NH—;
[0727] Z is a bond, —CH—, —O—, or —NH—;
[0728] W is a bond, —CH—, or —C(CH)H—;
[0729] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-;
[0730] L is a halogen;
[0731] R 1 , R 2A and R 2B are each independently hydrogen, halogen, —CN, —CF3, methyl, or —CONH2;
[0732] R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H -CO(C1-C3 alkyl), or -N(CH3)COO(C1-C3 alkyl),
[0733] R 5 and R 6 are each independently hydrogen or C1-C3 alkyl,
[0734] n1 is 0, 1, or 2;
[0735] n3 is 1 or 2.
[0736] In one embodiment of a compound of Formula (I), (IA), (IB), (IC), (II), (IIA), (IIB), (III), (IIIA), (IV), (V), (VA), or (VI) (represented as Formulas "(I)-(VI)"), A and B are each independently a 5- or 6-membered aryl or heteroaryl. In one embodiment, A and B are each independently selected from phenyl, pyridyl, pyrimidyl, or thiophene. In one embodiment, A and B are each phenyl.
[0737] In another embodiment, A has meta or para connectivity with X and Y. In some embodiments, B has meta or para connectivity with X and Z.
[0738] In one embodiment of the compounds of Formulae (I)-(VI), A and B are phenyl and have one of the connectivity shown below: [ka]
[0739] In one embodiment of a compound of Formulas (I)-(VA) and (A) (e.g., Formulas (I), (IA), (IB), (IC), (II), (IIA), (IIB), (III), (IIIA), (IV), (V), (VA), and (A)), C is aryl or heteroaryl. In some embodiments, C is a 5- to 10-membered aryl or heteroaryl. In other embodiments, C is aryl. In some embodiments, C is phenyl or naphthyl. In other embodiments, C is aryl. In some embodiments, C is phenyl.
[0740] In one embodiment of the compounds of Formulae (I)-(VA) and (A), C is heteroaryl. In one embodiment, C is monocyclic or bicyclic heteroaryl. In another embodiment, C is monocyclic heteroaryl. In some embodiments, C is 5-10 membered heteroaryl. In some embodiments, C is 5-6 membered heteroaryl, which may be selected from 1, 2, 3, 4, or 5 R3 In some embodiments, C is a 5-6 membered heteroaryl containing 1, 2, or 3 heteroatoms selected from O, S, or N, and the heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 R 3 In some embodiments, C is a 5-6 membered heteroaryl containing 1 or 2 heteroatoms selected from O, S, or N, and the heteroaryl is optionally substituted with 1, 2, 3, 4, or 5 R 3 is optionally replaced by
[0741] In one embodiment of a compound of Formula (I)-(VA), (A), or (D), C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, or pyrimidyl, which may each be selected from the group consisting of one, two, three, four, or five R 3 In one embodiment, C is optionally substituted with (R 3 In one embodiment, C is pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan, or pyrimidyl, each of which is substituted with one, two, three, four, or five R 3 is replaced by
[0742] In one embodiment of a compound of Formula (I)-(VA), (A), or (D), C is
[0743] [ka] [ka] wherein R 3ais C1-C3 alkyl. In one embodiment of a compound of Formula (I)-(VA), (A) or (D), C is [ka] [ka] wherein R 3a is C1-C3 alkyl.
[0744] In one embodiment of a compound of Formula (I)-(VA), (A), or (D), C is [ka] is.
[0745] In one embodiment, C is [ka] or its tautomeric form [ka] In one embodiment, C is [ka] or its tautomeric form [ka] is.
[0746] In one embodiment of a compound of Formula (I)-(IV), C is heterocyclyl. In one embodiment, C is a saturated or partially saturated heterocycle. In some embodiments, C is monocyclic or bicyclic. In some embodiments, C is a 5- to 7-membered heterocyclyl containing 1, 2, or 3 heteroatoms selected from O, S, or N as ring members.
[0747] In one embodiment of the compounds of Formulae (I)-(VA), (B) and (C), C is an imidazolidine, an imidazolidine-dione, or a dihydrooxazole. [ka] is selected from.
[0748] In one embodiment of the compounds of Formulae (I)-(VA), (B) and (C), C is [ka] and D is -O-, -NH- or -NR 3 -, and each U is independently O, S, or NR 16 In one embodiment, D is -NH- or -NR 3 In some embodiments, at least one U is O. In other embodiments, each U is O. In some embodiments, at least one R 3 is -SO2CH3, -NHSO2CH3, -CH2NHSO2CH3, -SO2NH2, -CONH2, or -NHCOCH3.
[0749] In one embodiment of a compound of Formula (I)-(VA), C is aryl. In some embodiments, C is phenyl or naphthyl. In one embodiment of a compound of Formula (I)-(VA) or (A), C is phenyl.
[0750] In one embodiment of the compounds of Formulae (I)-(VI), C is a bicyclic heteroaryl or heterocyclyl. [ka] is.
[0751] In one embodiment of the compounds of Formula (I), Z is a bond, —(CR 8 R 9 ) m-, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 In one embodiment, Z is -(CR 8 R 9 ) m -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 In some embodiments, Z is —C(═O)—.
[0752] In some embodiments of the compounds of Formulae (I)-(VI), (A), (B), and (C), Z is a bond, -CH-, -C(CH)H-, -O-, -S-, -NH-, -NCH-, or -N(COCH)-. In some embodiments, Z is -CH-, -C(CH)H-, -O-, -S-, -NH-, -NCH-, or -N(COCH)-. In some embodiments, Z is a bond, -CH-, -O-, or -NCH-. In some embodiments, Z is a bond, -CH-, -O-, or -NH-. In some embodiments of the compounds of Formulae (I)-(VI) and (A)-(HI), Z is -O-. As used herein, "compounds of formulae (I)-(IV) and (A)-(HI)" refers to compounds of formulae (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (AI), (B)-(D), (E), (EI)-(E-VII), (F), (G), (GI), (G-II), (H), and (HI).
[0753] In one embodiment of the compounds of Formula (I), Y is a bond, —(CR 8 R 9 ) m -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 In one embodiment, Y is -(CR 8 R 9 ) m -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7In some embodiments, Y is —C(═O)—.
[0754] In some embodiments of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), Y is a bond, -CH-, -C(CH)H-, -O-, -S-, -NH-, -NCH-, or -N(COCH)-. In some embodiments, Y is -CH-, -C(CH)H-, -O-, -S-, -NH-, -NCH-, or -N(COCH)-. In some embodiments, Y is a bond, -CH-, -O-, or -NCH-. In some embodiments, Y is a bond, -CH-, -O-, or -NH-. In some embodiments of the compounds of Formulae (I)-(VI) and (A)-(HI), Y is -O-.
[0755] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), V is a bond, —(CR 8a R 9a ) m In some embodiments, V is a bond or -(CR 8a R 9a ) m -It is.
[0756] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), V is -(CR 8a R 9a ) m -, where m is 1, 2, or 3. In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), V is -(CR 8a R 9a ) m -, wherein R 8a and R 8b each independently represents hydrogen, —OH, halogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C1-C3 alkoxy, —NR 13 R 14 , optionally substituted -(C1-C3 alkyl)-NR13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 or optionally substituted -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In one embodiment, V is -(CR 8a R 9a ) m -, wherein R 8a and R 8b each independently represents hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R on the same or different carbon atoms. 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl.
[0757] In one embodiment of compounds (I)-(IIB) and (VA), V is -CH2-, -CH2CH2-, -CH(CH3)CH2-, -CH2CH(CH3)-, or -CH2CH2CH2-.
[0758] In one embodiment of a compound of Formulas (I)-(VI), (A), (B), and (C), V is -CH-, -CHCH-, or -CHCHCH-, each optionally substituted with one or more of -OH, halogen, or C1-C3 alkyl. In other embodiments, V is -CH-, -CHCH-, -CHCH(OH)CH-, or -CHCHCH-. In some embodiments of a compound of Formulas (I)-(VI) and (A)-(HI), V is -CH-, -CHCH-, or -CHCHCH-. In some embodiments of a compound of Formulas (I)-(VI) and (A)-(HI), V is -CH- or -CHCH-.
[0759] In some embodiments of compounds of Formulae (I)-(VI) and (A)-(D), V is -CH- and L is halogen, -NH, or -CF, or V is -CHCH- and L is halogen or -NH.
[0760] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), L is hydrogen, halogen, —CFH, —CF, —CN, —O(C-C alkyl), —NR 11 R 12 , or -CONR 11 R 12 In one embodiment, L is hydrogen, halogen, -CFH, -CF, -CN, -O(C-C alkyl), -NH, -NH(C-C alkyl), -N(C-C alkyl), -CONH, -CONH(C-C alkyl), or -CON(C-C alkyl). In some embodiments, L is hydrogen, halogen, -CF, or -NH.
[0761] In some embodiments of compounds of Formula (IC) and (IIIA), L is a halogen, —CCl3, —CCl2, —CF3, or —NH2. In some embodiments of compounds of Formula (I)-(VI) and (A)-(HI), L is a halogen, —CF3, or —NH2. In one embodiment, L is hydrogen or a halogen. In one embodiment, L is a halogen. In another embodiment, L is Cl or Br. In one embodiment, L is Cl.
[0762] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), W is a bond. In one embodiment, W is -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-, -CONR 7 -, or -NSO2R 7 In one embodiment, W is -(CR 8a R 9a ) m -, where m is 1, 2, or 3. In some embodiments, W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -N(R 7 )CO- or -CONR 7 -, wherein R 7 is H or C1-C6 alkyl. In some embodiments, W is a bond, —CH2—, —C(CH3)H—, —C(═O)—, —N(R 7 )CO- or -CONR 7 -, wherein R 7 is H or C1-C3 alkyl. In one embodiment, W is a bond, -CH2-, -C(CH3)H-, -C(=O)-, -NHCO-, -N(C1-C3 alkyl)CO-, -CONH-, or -CON(C1-C3 alkyl)-. In one embodiment of a compound of Formulas (I)-(VI) and (A)-(E-VI), W is a bond, -CH2-, or -C(CH3)H-. In one embodiment of a compound of Formulas (I)-(VI) and (A)-(HI), W is -CH2- or -C(CH3)H-.
[0763] In one embodiment of a compound of Formulas (I)-(VI), (A), (B), and (C), -YW- is a bond, -OCH2-, -OCH2CH2-, -OCH(CH3)-, -NH-, -NHCH2-, -NHC(=O)-, or -C(=O)NH-. In one embodiment of a compound of Formulas (I)-(VI) and (A)-(HI), -YW- is -OCH2-, -OCH2CH2-, or -OCH(CH3)-.
[0764] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C):
[0765] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0766] V is -CH2-, -CH2CH2-, or -CH2CH2CH2-.
[0767] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C):
[0768] Z is a bond, -CH2-, -C(CH3)H-, -O-, -S-, -NH-, -NCH3-, or -N(COCH3)-;
[0769] V is -CH-, -CHCH-, or -CHCHCH-;
[0770] L is a halogen, -NH2, or -CF3.
[0771] In one embodiment of compounds of Formulae (I)-(VI), (A), (B), and (C), -ZVL is -Z-CH2CH2Cl, -Z-CH2CH2CH2Cl, -Z-CH2CH2NH2, or -Z-CH2CH2CH2NH2, where Z is a bond, -O-, -NH-, or -N(COCH3)-. In one embodiment, -ZVL is -OCH3.
[0772] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), -ZVL is -O-CH2CH2Cl or -O-CH2CH2CH2Cl.
[0773] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), -VL is -CH2CH2Cl, -CH2CH2CH2Cl, -CH2CH2NH2, or -CH2CH2CH2NH2. In one embodiment, -VL is -CH3.
[0774] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), X is a bond, —(CR 5 R 6 ) t -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 In one embodiment, X is a bond, -(CR 5 R 6 ) t -, -O-, -C(=O)-, -S-, -S(=O)-, -SO2-, or -NR 7 -, wherein R 7 is H or C1-C6 alkyl. In some embodiments, X is a bond, -(CR 5 R 6 ) t -, or -NR 7 In some embodiments, X is a bond or -(CR 5 R 6 ) t In some embodiments, X is a bond, —CH—, —C(CH)H—, —C(CH)—, —CHCH—, —NH—, or —N(C-C alkyl). In some embodiments, X is a bond, —CH—, —C(CH)H—, —C(CH)—, —CHCH—, —NH—, —N(CH)—, —N(CHCH)—, —N(iPr)—, or —N(tBu)—. In some embodiments, X is a bond, —CH—, —C(CH)H—, —C(CH)—, or —CHCH—.
[0775] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), X is -CH-, -C(CH)H-, or -C(CH)-. In one embodiment, X is -C(CH)-.
[0776] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 1 and R 2 are each independently halogen, -CN, -CF3, -OH, C1-C3 alkyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2R 16 , -(C1-C3 alkyl)-SO2R 16 , 3- to 7-membered carbocyclyl, 3- to 7-membered heterocyclyl, phenyl, or 5- to 6-membered heteroaryl.
[0777] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 1 and R 2are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C6 alkyl, optionally substituted C1-C6 alkoxy, optionally substituted —(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted —(C1-C6 alkyl)-OH, —NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 In one embodiment, R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF3, —OH, optionally substituted C1-C3 alkyl, C1-C3 alkoxy, optionally substituted —(C1-C3 alkyl)-(C1-C3 alkoxy), optionally substituted —(C1-C3 alkyl)-OH, —NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16, optionally substituted -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2R 16 or optionally substituted -(C1-C3 alkyl)-SO2R 16 In one embodiment, R 1 and R 2 are each independently hydrogen, halogen, -CN, -CF3, -OH, C1-C3 alkyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO2R 16 , or -(C1-C3 alkyl)-SO2R 16 is.
[0778] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 1 and R 2are each independently hydrogen, halogen, —CN, —CF3, —OH, C1-C3 alkyl, or —CONR 14 R 15 In some embodiments, R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF, —OH, methyl, methoxy, or —CONH. In one embodiment, R 1 and R 2 are each independently hydrogen, Cl, —CN, —CF, —OH, methyl, methoxy, or —CONH. In one embodiment, R 1 and R 2 are each independently hydrogen, halogen, —CN, —CF, —OH, or methyl. 1 and R 2 are each independently Cl, —CN, —CF, —OH, methyl, methoxy, or —CONH. In one embodiment of the compounds of Formulae (I)-(VI), R 1 and R 2 are each independently halogen, —CN, —CF 3 , —OH, or methyl.
[0779] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(EI), R 1 and R 2 are each halogen, methyl, —CF, or —CN. In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(F), R 1 and R 2 are each halogen or —CN. In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), R 1 and R 2 In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), at least one of R 1 and R 2 In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), at least two of R 1 and R 2 are each Cl or —CN.
[0780] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 1 and R 2 are each independently an optionally substituted carbocyclyl, an optionally substituted heterocyclyl, an optionally substituted aryl, or an optionally substituted heteroaryl. 1 and R 2 are each independently a 3- to 7-membered carbocyclyl, a 3- to 7-membered heterocyclyl, a phenyl, or a 5- or 6-membered heteroaryl.
[0781] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 1 has one of the connectivities for X and Y as shown below: [ka]
[0782] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 2 has one of the connectivities for X and Z as shown below: [ka]
[0783] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), n1 is 0, 1, or 2. In some embodiments, n1 is 0 or 1. In other embodiments, n1 is 0. In some embodiments, n1 is 1. In one embodiment, the sum of n1 and n2 is 0, 1, 2, 3, or 4. In some embodiments, the sum of n1 and n2 is 1, 2, 3, or 4. In one embodiment, the sum of n1 and n2 is 2.
[0784] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), n2 is 0, 1, or 2. In some embodiments, n2 is 1 or 2. In other embodiments, n2 is 0. In some embodiments, n2 is 1. In some embodiments, n2 is 2.
[0785] In some embodiments of compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), n3 is 1, 2, 3, 4, or 5. In some embodiments, n3 is 1, 2, 3, or 4. In one embodiment, n3 is 1, 2, or 3. In one embodiment, n3 is 1 or 2.
[0786] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 , optionally substituted -(C1-C6 alkyl)-SO2R 16 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, optionally substituted -(C1-C6 alkyl)-(C1-C6 alkoxy), optionally substituted -(C1-C6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C6 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C6 alkyl)-SO2R 16 In another embodiment, R 3is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -SR 16 , optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted C1-C3 alkoxy, optionally substituted -(C1-C3 alkyl)-(C1-C3 alkoxy), optionally substituted -(C1-C3 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , optionally substituted -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , optionally substituted -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , optionally substituted -(C1-C3 alkyl)-SO2NR 14 R 15 , optionally substituted -SO2R 16 or optionally substituted -(C1-C3 alkyl)-SO2R 16 is.
[0787] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 3 is -NR 14 SO2R 16 , optionally substituted -(C1-C6 alkyl)NR 14 SO2R 16 or optionally substituted -SO2R 16 wherein R 16is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, C3-C6 cycloalkyl, or phenyl. 3 is -NR 14 SO2R 16 , -(C1-C6 alkyl)NR 14 SO2R 16 , or -SO2R 16 wherein R 16 is hydrogen, C1-C3 alkyl, -(C1-C3 alkyl)-NH2, C3-C6 cycloalkyl, or phenyl.
[0788] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R 3 is hydrogen, halogen, oxo, =S, =NR 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15, —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl). In some embodiments, R 3 is hydrogen, F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl). In some embodiments, R 3 is hydrogen, F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl). In one embodiment, R 3 is hydrogen, F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, methyl, -SCH3, -SO2CH3, -NHSO2CH3, -NHSO2CH2CH3, -CH2NHSO2CH3, -SO2NH2, -CONH2, or -NHCOCH3. In one embodiment, R 3 is hydrogen, F, Cl, Br, I, oxo, =S, =NR 16, —CN, —CF, —OH, methyl, —SCH, —SOCH, —NHSOCH, —CHNHSOCH, —SONH, —CONH, or —NHCOCH. In some embodiments, R 3 are F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl). In some embodiments, R 3 are F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, -S(C1-C3 alkyl), -SO(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NHSO2CH3, -N(CH3)SO2CH3, NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), or -N(CH3)CO(C1-C3 alkyl). In one embodiment, R 3 are F, Cl, Br, I, oxo, =S, =NR 16 , -CN, -CF3, -OH, methyl, -SCH3, -SO2CH3, -NHSO2CH3, -CH2NHSO2CH3, -SO2NH2, -CONH2, or -NHCOCH3. In another embodiment, R 3 is —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SO2NH2, —CONH2, or —NHCOCH3. In one embodiment, R 3 is oxo, =S, =NR 16, C1-C3 alkyl, —SO2(C1-C3 alkyl), or —NHSO2(C1-C3 alkyl). In one embodiment, R 3 At least one of the groups is oxo, ═S, or ═NR 16 In one embodiment, R 3 At least one of the groups is oxo, ═S, or ═NR 16 where R 16 is H or C1-C3 alkyl.
[0789] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(E-VII), R 3 represents hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(E-VII), R 3 is hydrogen, F, Cl, Br, I, oxo, -CN, -CF3, -OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 )COO(C1-C3 alkyl), -N H It is selected from —CO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
[0790] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), sp 3 R on carbon 3 are hydrogen, halogen, oxo, =S, and =NR, respectively. 16 , -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , -SO(C1-C3 alkyl), -SO2(C1-C3 alkyl), or -(C1-C6 alkyl)-SO2(C1-C3 alkyl). 3 R on carbon 3 is oxo, =S, or =NR 16 If the carbon is sp 2 This becomes:
[0791] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), sp 2 R on carbon 3are each hydrogen, halogen, -CN, -CF3, -OH, -S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl).
[0792] In one embodiment of the compounds of Formulae (I)-(VI), (A), (AI), (B), and (C), R on the nitrogen atom 3 are respectively C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -(C1-C3 alkyl)-(C1-C3 alkoxy), -(C1-C3 alkyl)-OH, and -(C1-C3 alkyl)-NR 13 R 14 , -(C1-C3 alkyl)NR 14 SO2R 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -(C1-C3 alkyl)-SO2NR14 R 15 or -(C1-C6 alkyl)-SO2(C1-C3 alkyl).
[0793] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(G-II), at least one R 3 is selected from -CN, C1-C3 alkoxy, -CONH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, or -SO2CH3, and other R 3 When present, -CN, -CF3, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -S(C1-C3 alkyl), -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -NHSO2CF3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -CH2NHSO2CH3, -CH2N(CH3)SO2CH3, -SON2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N H In one embodiment, at least one R 3 is selected from -NHSO2CH3, -NHSO2CH2CH3, or -SO2CH3, and other R 3 When present, -CN, C1-C3 alkyl, C1-C3 alkoxy, -SO2(C1-C3 alkyl), -NH2, -(C1-C3 alkyl)NH2, -NHSO2CH3, -N(CH3)SO2CH3, -NHSO2CH2CH3, -N(CH3)SO2CH2CH3, -SO2NH2, -CONH2, -CON(C1-C3 alkyl)2, -CONH(C1-C3 alkyl), -NHCO(C1-C3 alkyl), -N (CH 3 ) COO(C1-C3 alkyl), -N HIt is selected from —CO(C1-C3 alkyl), or —N(CH3)COO(C1-C3 alkyl).
[0794] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(E-II), R 3 is not hydrogen.
[0795] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(G-II), at least one R 3 is -SO2CH3, -NHSO2CH3, -NCH3SO2CH3, -NHSO2CH2CH3, or -N(CH3)SO2CH2CH3. In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(G-II), at least one R 3 is -SO2CH3, -NHSO2CH3, or -NCH3SO2CH3.
[0796] In one embodiment of a compound of Formula (I), (IA), (IB), or (IC), R 3 is heterocyclyl. In one embodiment, R 3 teeth, [ka] is a heterocyclyl selected from:
[0797] In one embodiment of the compound of Formula (IB), (IC), (IIA), or (IIB), R 3 Ha-NR 14 SO2R 16 where R 14 and R 16 together form a 5- or 6-membered ring containing a nitrogen atom and a sulfur atom.
[0798] In one embodiment of a compound of Formula (I), (IA), (IB), or (IC), R 3 Ha-NR 14 SO2R 16 where R 16 is optionally substituted C1-C6 alkyl. In one embodiment, R 3 Ha-NR14 SO2R 16 where R 16 is C1-C6 alkyl optionally substituted with one or more groups selected from halogen, -CN, -CF3, -OH, C1-C3 alkyl, C1-C3 alkoxy, -NH2, -NH(C1-C3 alkyl), -N(C1-C3 alkyl)2, and -SCH3. 3 Ha-NR 14 SO2R 16 where R 16 is a C1-C3 alkyl substituted with -NH2.
[0799] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 5 and R 6 are each independently hydrogen, halogen, —OH, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, or C1-C3 alkoxy, or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In some embodiments, R 5 and R 6 are each independently hydrogen, halogen, —OH, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. 5 and R 6 is hydrogen, halogen, —OH, or C1-C3 alkyl. 5 and R 6 are each independently hydrogen, F, —OH, or C1-C3 alkyl. 5 and R 6 are each independently hydrogen, F, —OH, or methyl. In one embodiment, R 5 and R 6 are each H. In one embodiment, R 5 and R 6 and each is methyl. In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), R 5 and R6 are each H or methyl.
[0800] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 7 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 7 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. 7 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. 7 is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments, R 7 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl. In some embodiments, R 7 is hydrogen or C1-C6 alkyl. In some embodiments, R 7 is hydrogen or C1-C4 alkyl. In some embodiments of compounds of Formulas (I)-(VI) and (A)-(HI), R 7 is hydrogen or C1-C3 alkyl.
[0801] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R8a and R 9a are each independently hydrogen, halogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted C1-C6 alkoxy, -NR 13 R 14 , optionally substituted -(C1-C6 alkyl)-NR 13 R 14 , -NR 14 COR 16 , optionally substituted -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , optionally substituted -(C1-C6 alkyl)-CONR 14 R 15 , optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl, or R 8a and R 9a together form an optionally substituted carbocyclyl or an optionally substituted heterocyclyl. In some embodiments, R 8a and R 8b are each independently hydrogen, -OH, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 or R 8a and R 8b together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl. In one embodiment, R 8a and R 9aare each independently hydrogen, halogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, -NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 COR 16 , -(C1-C3 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , or -(C1-C3 alkyl)-CONR 14 R 15 In one embodiment of a compound of formula (IB), (IC), (III), or (IIIA), R 8a and R 9a is not —OH. In one embodiment, R 8a and R 9a is not -OH.
[0802] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 7 and R 8a together form an optionally substituted heterocyclyl. In one embodiment, R 7 and R 8a together form an optionally substituted 3- to 7-membered heterocycle.
[0803] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 8 and R 9 are each independently hydrogen, halogen, or C1-C3 alkyl.
[0804] In one embodiment of the compounds of Formula (I)-(IIB), R 10 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 10is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 10 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. 10 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl. In some embodiments, R 10 is hydrogen or C1-C3 alkyl.
[0805] In one embodiment of the compounds of Formula (I)-(IIB), R 11 and R 12 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. 11 and R 12 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments, R 11 and R 12 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. 11 and R 12 are each independently hydrogen or C1-C3 alkyl.
[0806] In one embodiment of the compounds of Formula (I)-(IIB), R 11 and R 12 together form an optionally substituted heterocyclyl. In one embodiment, R11 and R 12 together form an optionally substituted 3- to 7-membered heterocyclyl. In another embodiment, R 11 and R 12 together form a 3- to 7-membered heterocyclyl.
[0807] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 13 and R 14 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. 13 and R 14 are each independently hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments, R 13 and R 14 are each independently hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. 13 and R 14 are each independently hydrogen or C1-C3 alkyl.
[0808] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 15 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. 15 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, or optionally substituted C2-C6 alkynyl. In some embodiments, R 15is hydrogen, C1-C6 alkyl, C2-C6 alkenyl, or C2-C6 alkynyl. In some embodiments, R 15 is hydrogen or C1-C3 alkyl.
[0809] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 14 and R 15 together form an optionally substituted heterocyclyl. In one embodiment, R 14 and R 15 together form an optionally substituted 3- to 7-membered heterocyclyl. In another embodiment, R 14 and R 15 together form a 3- to 7-membered heterocyclyl.
[0810] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), R 16 is hydrogen, optionally substituted C1-C6 alkyl, optionally substituted C2-C6 alkenyl, optionally substituted C2-C6 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 16 is hydrogen, optionally substituted C1-C3 alkyl, optionally substituted C2-C3 alkenyl, optionally substituted C2-C3 alkynyl, optionally substituted carbocyclyl, optionally substituted heterocyclyl, optionally substituted aryl, or optionally substituted heteroaryl. In some embodiments, R 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, carbocyclyl, heterocyclyl, aryl, or heteroaryl. 16 is hydrogen, C1-C3 alkyl, C2-C3 alkenyl, or C2-C3 alkynyl. In some embodiments, R 16 is hydrogen or C1-C3 alkyl.
[0811] In one embodiment of the compounds of Formulae (I)-(IIIA), m is 1 or 2.
[0812] In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(F), t is 1 or 2. In one embodiment of the compounds of Formulae (I)-(VI) and (A)-(HI), t is 1.
[0813] In one embodiment of the compounds of Formulae (I)-(VI), (A), (B), and (C), the optional substituents are selected from the group consisting of halogen, —CN, —CF, —OH, —S(C1-C3 alkyl), C1-C3 alkyl, C2-C3 alkenyl, C2-C3 alkynyl, C1-C3 alkoxy, —(C1-C3 alkyl)-(C1-C3 alkoxy), —(C1-C3 alkyl)-OH, —NR 13 R 14 , -(C1-C3 alkyl)-NR 13 R 14 , -NR 14 SO2R 16 , -(C1-C3 alkyl)NR 14 SO2R 16 , -NR 14 COR 16 , -(C1-C6 alkyl)-NR 14 COR 16 , -CONR 14 R 15 , -(C1-C3 alkyl)-CONR 14 R 15 , -SO2NR 14 R 15 , -(C1-C3 alkyl)-SO2NR 14 R 15 , —SO(C1-C3 alkyl), —SO2(C1-C3 alkyl), or —(C1-C6 alkyl)-SO2(C1-C3 alkyl). In another embodiment, the optional substituents are selected from halogen, —CN, —CF3, —OH, C1-C3 alkyl, C1-C3 alkoxy, —NH2, —SCH3, —SO2CH3, —NHSO2CH3, —CH2NHSO2CH3, —SON2NH2, —CONH2, or —NHCOCH3.
[0814] In one embodiment of the compounds of Formulae (I)-(VI), A and B are each monocyclic rings.
[0815] In one embodiment of the compounds of Formulae (I)-(VI), B is phenyl, pyridyl, or pyrimidyl.
[0816] In one embodiment of the compounds of Formula (I)-(IIIA), Z and V are not both bonds.
[0817] In one embodiment of the compounds of Formulae (I)-(VI), (A)-(C), Y and W are not both bonds.
[0818] In one embodiment of the compounds of Formulae (I)-(VI), C is a 4-10 membered ring.
[0819] In one embodiment of a compound of Formula (D)-(HI), X is a bond, -CH2-, -C(CH3)H-, -C(CH3)2-, or -CH2CH2-. In one embodiment, X is -CH2-, -C(CH3)H-, or -C(CH3)2-. In some embodiments, X is -C(CH3)2-.
[0820] In one embodiment of the compounds of Formulae (D)-(H), X is —NR 7 In one embodiment, X is —NH—, —N(CH 3 )—, —N(CH 2 CH 3 )—, —N(iPr)—, or —N(tBu)—.
[0821] In one embodiment of a compound of Formula (D)-(HI), Y is -O-. In one embodiment of a compound of Formula (D)-(HI), Z is -O-. In one embodiment of a compound of Formula (D)-(HI), Y and Z are both -O-.
[0822] In one embodiment of a compound of Formula (D)-(HI), -VL is CH2CH2Cl, -CH2CH2CH2Cl, or -CH3. In some embodiments, -VL is CH2CH2Cl or -CH2CH2CH2Cl.
[0823] In one embodiment of the compounds of Formulae (D)-(HI), n1 is 0.
[0824] In one embodiment of a compound of Formula (D)-(HI), n2 is 0, 1, or 2. In some embodiments, n2 is 2. In some embodiments, n2 is 2 and R 2 are each ortho to Z. In other embodiments, n2 is 2 and R 2 are each ortho to Z, where R 2 is a halogen or -CN.
[0825] In some embodiments of the compounds of Formulae (I)-(VI) and (A)-(HI), the compounds may be stereoisomers. For example, X may be -(CR 5 R 6 )- and R 5 and R 6 If different, R 5 and R 6 The carbon attached to may be in the S or R configuration.
[0826] In some embodiments of the compounds of Formulae (I)-(VI) and (A)-(HI), a hydrogen atom may be replaced with a deuterium atom.
[0827] In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from Table A below, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), or (D)-(HI), the compound is selected from compound A3, A5, A7, A13, A17, A18, A22, A23, A24, A25, A28, A30, A31, A32, A34, A35, A38, A40, A41, A42, A45, A49, A52, A53, A54, A56, A57, A58, A62, A63, A64, A65, A68, A73, A74, A75, or A76, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from the group consisting of Compounds A1, A2, A4, A6, A8, A9, A10, A11, A12, A14, A15, A16, A19, A20, A21, A26, A27, A29, A33, A36, A37, A39, A43, A44, A46, A47, A48, A50, A51, A55, A56, A57, A58, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104, A105, A106, A107, A108, A109, A110, A111, A120, A121, A122, A123, A124, A125, A126, A127, A130, A131, A132, A133, A134, A135, A136, A137, A140, A141, A142, A143, A144, A145, A146, A147, A In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A98-A186, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A187-A211, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A1-A211, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A212-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A1-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from compounds A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.
[0828] In one embodiment of a compound of Formula (I)-(VA), (A), (AI), or (D)-(HI), the compound is selected from A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and / or A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.
[0829] [Table A-1] [Table A-2] [Table A-3] [Table A-4] [Table A-5]
Table A-6
Table A-7
Table A-8
Table A-9
Table A-10
Table A-11
Table A-12
Table A-13
Table A-14
Table A-15
Table A-16
Table A-17
Table A-18
Table A-19
Table A-20
Table A-21
Table A-22
Table A-23
Table A-24
Table A-25
Table A-26
Table A-27
Table A-28
Table A-29
Table A-30
Table A-31
[0830] In one embodiment of a compound of Formula (I)-(IV), (VI), (B) or (C), the compound is selected from Table B below, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of a compound of Formula (I)-(IV), (VI), (B) or (C), the compound is selected from compound B1, B2, B3, or B6, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of a compound of Formula (I)-(IV), (VI), (B) or (C), the compound is selected from compound B4, B5, B7, B8, B9, B10, or B11, or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof. In one embodiment of the compound of Formula (I)-(IV), (VI), (B) or (C), the compound is selected from compounds B1-B11 or a pharmaceutically acceptable salt, tautomer, stereoisomer or prodrug thereof.
[0831] [Table B-1] [Table B-2]
[0832] In one embodiment, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound of any one of Formulas (I), (IA), (IB), (IC), (II), (IIA), (IIIA), (IIB), (III), (IV), (IVA), (V), (VA), (VI), (A), (AI), (B)-(D), (E), (EI)-(E-VII), (F), (G), (GI), (G-II), (H), and (HI) (“Formulas (I)-(VI) and (A)-(HI)”) or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound selected from compound A3, A5, A7, A13, A17, A18, A22, A23, A24, A25, A28, A30, A31, A32, A34, A35, A38, A40, A41, A42, A45, A49, A52, A53, A54, A56, A57, A58, A62, A63, A64, A65, A68, A73, A74, A75, A76, B1, B2, B3, or B6, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the present disclosure provides a method for treating a rhodium-containing ... and a pharmaceutical composition comprising a compound selected from A70, A71, A72, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, B4, B5, B7, B8, B9, B10, or B11, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound selected from compounds A98 to A186, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound selected from compounds A187 to A211, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound selected from compounds A212 to A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound selected from compounds A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound selected from compounds A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and / or A204, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or excipient and a compound selected from compounds A1-A211 or B1-B11, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound selected from compounds A1-A234 or B1-B11, or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.In one embodiment, the present disclosure provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier or a pharmaceutically acceptable excipient and a compound of any one of Formulas (D)-(HI), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof.
[0833] therapeutic use The compounds find use in a number of methods. For example, in some embodiments, the compounds are useful in methods for modulating the androgen receptor (AR). Thus, in one embodiment, the present disclosure provides the use of any one of the aforementioned compounds of Formulas (I)-(VI) and (A)-(HI), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof, for modulating androgen receptor (AR) activity. For example, in some embodiments, modulation of androgen receptor (AR) activity is performed in mammalian cells. Modulation of the androgen receptor (AR) can be performed in a subject (e.g., a mammalian subject) in need thereof, for the treatment of any of the conditions or diseases described.
[0834] In one embodiment, the modulation of AR is binding to AR, hi another embodiment, the modulation of AR is inhibiting AR.
[0835] In one embodiment, the modulation of AR is to modulate AR N-terminal domain (NTD). In one embodiment, the modulation of AR is to bind to AR NTD. In other embodiments, the modulation of AR is to inhibit AR NTD. In one embodiment, the modulation of AR is to modulate AR N-terminal domain (NTD). In some embodiments, the modulation of AR is to inhibit the transactivation of androgen receptor N-terminal domain (NTD).
[0836] In other embodiments, the modulation of androgen receptor (AR) activity is intended to treat at least one indication selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, bladder cancer, pancreatic cancer, hepatocellular carcinoma, endometrial cancer, salivary gland cancer, alopecia, acne, hirsutism, ovarian cysts, polycystic ovarian disease, precocious puberty, spinal-bulbar muscular atrophy, age-related macular degeneration, and combinations thereof.For example, in some embodiments, the indication is prostate cancer.In other embodiments, the prostate cancer is primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, non-metastatic castration-resistant prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer.In other embodiments, the prostate cancer is androgen-dependent prostate cancer.In other embodiments, the spinal-bulbar muscular atrophy is Kennedy's disease. In another embodiment, the prostate cancer is primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, or metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer, while in another embodiment, the prostate cancer is androgen-dependent prostate cancer. In another embodiment, the spinal-bulbar muscular atrophy is Kennedy's disease.
[0837] In one embodiment of the present disclosure, a method of treating a condition associated with cell proliferation in a patient in need thereof is provided, the method comprising administering to a subject in need thereof a compound of Formulae (I)-(VI) and (A)-(HI), or a pharmaceutically acceptable salt, tautomer, stereoisomer, or prodrug thereof. In one embodiment, the present invention provides a method of treating cancer or tumors. In another embodiment, the present invention provides a method of treating prostate cancer or breast cancer.
[0838] In one embodiment of the present disclosure, a method of reducing, inhibiting, or ameliorating proliferation is provided comprising administering a therapeutically effective amount of a compound of Formulae (I)-(VI) and (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In one embodiment, the reduction, inhibition, or amelioration in the methods disclosed herein is in vivo. In another embodiment, the reduction, inhibition, or amelioration is in vitro.
[0839] In one embodiment, the cells in the method disclosed herein are cancer cells. In one embodiment, the cancer cells are prostate cancer cells. In one embodiment, the prostate cancer cells are cells of primary / localized prostate cancer (newly diagnosed or early stage), locally advanced prostate cancer, recurrent prostate cancer (e.g., prostate cancer that has not responded to a first therapy), metastatic prostate cancer, non-metastatic castration-resistant prostate cancer, advanced prostate cancer (e.g., after castration for recurrent prostate cancer), metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In one embodiment, the prostate cancer cells are cells of primary / localized prostate cancer (newly diagnosed or early stage), locally advanced prostate cancer, recurrent prostate cancer (e.g., prostate cancer that has not responded to a first therapy), metastatic prostate cancer, advanced prostate cancer (e.g., after castration for recurrent prostate cancer), metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In another embodiment, the prostate cancer cells are cells of metastatic castration-resistant prostate cancer. In other embodiments, the prostate cancer cells are androgen-dependent or androgen-independent prostate cancer cells. In one embodiment, the cancer cells are breast cancer cells.
[0840] In one embodiment, the condition or disease associated with cell proliferation is cancer. In one embodiment of any one of the methods disclosed herein, the cancer is selected from the group consisting of prostate cancer, breast cancer, ovarian cancer, endometrial cancer, salivary gland cancer, alopecia, acne, hirsutism, ovarian cysts, polycystic ovarian disease, precocious puberty, spinal-bulbar muscular atrophy, and age-related macular degeneration. In one embodiment, the condition or disease is prostate cancer. In one embodiment, the prostate cancer is selected from primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, non-metastatic castration-resistant prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In one embodiment, the prostate cancer is selected from primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer. In another embodiment, the prostate cancer is metastatic castration-resistant prostate cancer. In some embodiments, the prostate cancer is androgen-dependent prostate cancer cells or androgen-independent prostate cancer. In one embodiment, the condition or disease is breast cancer.
[0841] In another embodiment of the present disclosure, a method of reducing or preventing tumor growth is provided comprising contacting tumor cells with a therapeutically effective amount of a compound of (I)-(VI) and (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0842] In one embodiment, reducing or preventing tumor growth comprises reducing tumor volume. In one embodiment, reducing or preventing tumor growth comprises completely eliminating the tumor. In one embodiment, reducing or preventing tumor growth comprises arresting or halting the growth of an existing tumor. In one embodiment, reducing or preventing tumor growth comprises reducing the tumor growth rate. In one embodiment, reducing or preventing tumor growth comprises reducing the tumor growth rate such that the tumor growth rate before treating a patient with the methods disclosed herein (r1) is faster than the tumor growth rate after treatment (r2), i.e., r1 > r2.
[0843] In one embodiment, the reduction or prevention in the methods disclosed herein is in vivo, hi another embodiment, the treatment is in vitro.
[0844] In one embodiment, the tumor cells in the methods disclosed herein are selected from prostate cancer, breast cancer, ovarian cancer, endometrial cancer, or salivary gland cancer. In one embodiment, the tumor cells are prostate cancer tumor cells. In one embodiment, the prostate cancer tumor cells are primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, non-metastatic castration-resistant prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer tumor cells. In one embodiment, the prostate cancer tumor cells are primary / localized prostate cancer, locally advanced prostate cancer, recurrent prostate cancer, metastatic prostate cancer, advanced prostate cancer, metastatic castration-resistant prostate cancer (CRPC), or hormone-sensitive prostate cancer tumor cells. In other embodiments, the prostate cancer is metastatic castration-resistant prostate cancer. In some embodiments, the prostate cancer is androgen-dependent prostate cancer or androgen-independent prostate cancer. In another embodiment, the tumor cells are breast cancer tumor cells.
[0845] According to another embodiment, there is provided the use of a compound of Formulas (I)-(VI) and (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for the preparation of a medicament for modulating the androgen receptor (AR). In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound provides metabolic stability. In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human liver microsomes (HLM) of less than about 500 μL / min / mg protein, less than about 450 μL / min / mg protein, less than about 400 μL / min / mg protein, less than about 350 μL / min / mg protein, less than about 300 μL / min / mg protein, less than about 250 μL / min / mg protein, less than about 225 μL / min / mg protein, or less than about 200 μL / min / mg protein.In some embodiments, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has a flow rate of less than about 200 μL / min / mg protein, less than about 190 μL / min / mg protein, less than about 180 μL / min / mg protein, less than about 170 μL / min / mg protein, less than about 160 μL / min / mg protein In some embodiments, the HLM has an in vitro metabolic clearance of less than about 150 μL / min / mg protein, less than about 140 μL / min / mg protein, less than about 130 μL / min / mg protein, less than about 120 μL / min / mg protein, less than about 110 μL / min / mg protein, less than about 100 μL / min / mg protein, less than about 90 μL / min / mg protein, less than about 80 μL / min / mg protein, less than about 70 μL / min / mg protein, less than about 60 μL / min / mg protein, or less than about 50 μL / min / mg protein. In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HLM of less than about 50 μL / min / mg protein, less than about 48 μL / min / mg protein, less than about 45 μL / min / mg protein, less than about 40 μL / min / mg protein, less than about 35 μL / min / mg protein, less than about 30 μL / min / mg protein, less than about 25 μL / min / mg protein, less than about 20 μL / min / mg protein, or less than about 15 μL / min / mg protein.In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HLM of less than about 15 μL / min / mg protein, less than about 14 μL / min / mg protein, less than about 13 μL / min / mg protein, less than about 12 μL / min / mg protein, less than about 11 μL / min / mg protein, or less than about 10 μL / min / mg protein.
[0846] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of HLM of less than 12 μL / min / mg protein. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of HLM that is within the range of about 0.1 μL / min / mg protein to about 12 μL / min / mg protein. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of HLM of less than 48 μL / min / mg protein. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of HLM that is within the range of about 12 μL / min / mg protein to about 48 μL / min / mg protein. In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HLM that is in the range of about 0.1 μL / min / mg protein to about 48 μL / min / mg protein.
[0847] In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM in vitro metabolic clearance of less than about 20 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM in vitro metabolic clearance of less than about 15 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0848] In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an HLM in vitro metabolic clearance of less than about 20 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an HLM in vitro metabolic clearance of less than about 15 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an HLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an HLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0849] In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse liver microsomes (MLM) of less than about 500 μL / min / mg protein, less than about 450 μL / min / mg protein, less than about 400 μL / min / mg protein, less than about 350 μL / min / mg protein, less than about 300 μL / min / mg protein, less than about 250 μL / min / mg protein, less than about 225 μL / min / mg protein, or less than about 200 μL / min / mg protein. In some embodiments, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has a flow rate of less than about 200 μL / min / mg protein, less than about 190 μL / min / mg protein, less than about 180 μL / min / mg protein, less than about 170 μL / min / mg protein, less than about 160 μL / min / mg protein In some embodiments, the MLM has an in vitro metabolic clearance of less than about 150 μL / min / mg protein, less than about 140 μL / min / mg protein, less than about 130 μL / min / mg protein, less than about 120 μL / min / mg protein, less than about 110 μL / min / mg protein, less than about 100 μL / min / mg protein, less than about 90 μL / min / mg protein, less than about 80 μL / min / mg protein, less than about 70 μL / min / mg protein, less than about 60 μL / min / mg protein, or less than about 50 μL / min / mg protein.In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM of less than about 50 μL / min / mg protein, less than about 48 μL / min / mg protein, less than about 45 μL / min / mg protein, less than about 40 μL / min / mg protein, less than about 35 μL / min / mg protein, less than about 30 μL / min / mg protein, less than about 25 μL / min / mg protein, less than about 20 μL / min / mg protein, or less than about 15 μL / min / mg protein. In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM of less than about 15 μL / min / mg protein, less than about 14 μL / min / mg protein, less than about 13 μL / min / mg protein, less than about 12 μL / min / mg protein, less than about 11 μL / min / mg protein, or less than about 10 μL / min / mg protein.
[0850] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM of less than 12 μL / min / mg protein. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM of less than 12 μL / min / mg protein. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM of less than 48 μL / min / mg protein. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM that is within the range of about 12 μL / min / mg protein to about 48 μL / min / mg protein. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MLM that is within the range of about 0.1 μL / min / mg protein to about 48 μL / min / mg protein.
[0851] In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an MLM in vitro metabolic clearance of less than about 20 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an MLM in vitro metabolic clearance of less than about 15 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0852] In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an MLM in vitro metabolic clearance of less than about 20 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an MLM in vitro metabolic clearance of less than about 15 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0853] In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human hepatocytes (HH) of less than about 500 μL / min / million cells, less than about 450 μL / min / million cells, less than about 400 μL / min / million cells, less than about 350 μL / min / million cells, less than about 300 μL / min / million cells, less than about 250 μL / min / million cells, less than about 225 μL / min / million cells, or less than about 200 μL / min / million cells. In some embodiments, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has a flow rate of less than about 200 μL / min / 1 million cells, less than about 190 μL / min / 1 million cells, less than about 180 μL / min / 1 million cells, less than about 170 μL / min / 1 million cells, less than about 160 μL / min / 10 million cells, or less than about 200 μL / min / 1 million cells, ... In some embodiments, the HH has an in vitro metabolic clearance of less than about 0 million cells, less than about 150 μL / min / 1 million cells, less than about 140 μL / min / 1 million cells, less than about 130 μL / min / 1 million cells, less than about 120 μL / min / 1 million cells, less than about 110 μL / min / 1 million cells, less than about 100 μL / min / 1 million cells, less than about 90 μL / min / 1 million cells, less than about 80 μL / min / 1 million cells, less than about 70 μL / min / 1 million cells, less than about 60 μL / min / 1 million cells, or less than about 50 μL / min / 1 million cells.In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(H1), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than about 50 μL / min / million cells, less than about 48 μL / min / million cells, less than about 45 μL / min / million cells, less than about 40 μL / min / million cells, less than about 35 μL / min / million cells, less than about 30 μL / min / million cells, less than about 25 μL / min / million cells, less than about 20 μL / min / million cells, or less than about 15 μL / min / million cells. In some embodiments, compounds of the present disclosure have an in vitro metabolic clearance of HH of less than about 15 μL / min / million cells, less than about 14 μL / min / million cells, less than about 13 μL / min / million cells, less than about 12 μL / min / million cells, less than about 11 μL / min / million cells, less than about 10 μL / min / million cells, less than about 9 μL / min / million cells, less than about 8 μL / min / million cells, less than about 8 μL / min / million cells, less than about 6 μL / min / million cells, or less than about 5 μL / min / million cells.
[0854] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than 4 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH that is within the range of about 0.1 μL / min / million cells to about 4 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than 18 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH that is within the range of about 4 μL / min / million cells to about 18 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH that is within the range of about 0.1 μL / min / million cells to about 18 μL / min / million cells.
[0855] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than about 20 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than about 10 μL / min / million cells. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than about 5 μL / min / million cells. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of HH of less than about 3.85 μL / min / million cells.
[0856] In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of HH of less than about 20 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of HH of less than about 10 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of HH of less than about 5 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human hepatocytes of less than about 3.85 μL / min / million cells.
[0857] In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse hepatocytes (MH) of less than about 500 μL / min / million cells, less than about 450 μL / min / million cells, less than about 400 μL / min / million cells, less than about 350 μL / min / million cells, less than about 300 μL / min / million cells, less than about 250 μL / min / million cells, less than about 225 μL / min / million cells, or less than about 200 μL / min / million cells. In some embodiments, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has a flow rate of less than about 200 μL / min / 1 million cells, less than about 190 μL / min / 1 million cells, less than about 180 μL / min / 1 million cells, less than about 170 μL / min / 1 million cells, less than about 160 μL / min / 10 million cells, or less than about 200 μL / min / 1 million cells, ... In some embodiments, the MH has an in vitro metabolic clearance of less than about 0 million cells, less than about 150 μL / min / 1 million cells, less than about 140 μL / min / 1 million cells, less than about 130 μL / min / 1 million cells, less than about 120 μL / min / 1 million cells, less than about 110 μL / min / 1 million cells, less than about 100 μL / min / 1 million cells, less than about 90 μL / min / 1 million cells, less than about 80 μL / min / 1 million cells, less than about 70 μL / min / 1 million cells, less than about 60 μL / min / 1 million cells, or less than about 50 μL / min / 1 million cells.In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 50 μL / min / million cells, less than about 48 μL / min / million cells, less than about 45 μL / min / million cells, less than about 40 μL / min / million cells, less than about 35 μL / min / million cells, less than about 30 μL / min / million cells, less than about 25 μL / min / million cells, less than about 20 μL / min / million cells, or less than about 15 μL / min / million cells. In some embodiments, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has a flow rate of less than about 15 μL / min / million cells, less than about 14 μL / min / million cells , has an in vitro metabolic clearance of MH of less than about 13 μL / min / 1 million cells, less than about 12 μL / min / 1 million cells, less than about 11 μL / min / 1 million cells, less than about 10 μL / min / 1 million cells, less than about 9 μL / min / 1 million cells, less than about 8 μL / min / 1 million cells, less than about 8 μL / min / 1 million cells, less than about 6 μL / min / 1 million cells, or less than about 5 μL / min / 1 million cells.
[0858] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than 4 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH that is within the range of about 0.1 μL / min / million cells to about 4 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than 18 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH that is within the range of about 4 μL / min / million cells to about 18 μL / min / million cells. In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH that is within the range of about 0.1 μL / min / million cells to about 18 μL / min / million cells.
[0859] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 20 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 17 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 7 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 3.85 μL / min / million cells.
[0860] In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of MH of less than about 20 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of MH of less than about 17 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro metabolic clearance of MH of less than about 7 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A or B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH of less than about 3.85 μL / min / million cells.
[0861] In another embodiment, the compound of the present disclosure is any compound that combines the in vitro metabolic clearance of HLM, MLM, HH, and MH as described herein.
[0862] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have HLM and MLM in vitro metabolic clearances of less than about 20 μL / min / mg protein. In another embodiment, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have HLM and MLM in vitro metabolic clearances of less than about 15 μL / min / mg protein. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0863] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 20 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 15 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein.
[0864] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human and mouse hepatocytes of less than about 20 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse hepatocytes of less than about 17 μL / min / million cells and less than about 10 μL / min / million cells. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse hepatocytes of less than about 7 μL / min / million cells and an in vitro metabolic clearance in human hepatocytes of less than about 5 μL / min / million cells. In another embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human and mouse hepatocytes of less than about 3.85 μL / min / million cells.
[0865] In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human and mouse hepatocytes of less than about 20 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse hepatocytes of less than about 17 μL / min / million cells and an in vitro metabolic clearance in human hepatocytes of less than about 10 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in mouse hepatocytes of less than about 7 μL / min / million cells and an in vitro metabolic clearance in human hepatocytes of less than about 5 μL / min / million cells. In another embodiment, the compound of the disclosure is any compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance in human and mouse hepatocytes of less than about 3.85 μL / min / million cells.
[0866] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 20 μL / min / mg protein and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 20 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 15 μL / min / mg protein, and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 17 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein, and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 7 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein, and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 3.85 μL / min / million cells.
[0867] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM or MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein and b) an in vitro metabolic clearance of human or mouse hepatocytes of less than about 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein and b) an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein and b) an in vitro metabolic clearance of human or mouse hepatocytes of less than about 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM or MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein and b) an in vitro metabolic clearance of human and mouse hepatocytes of less than about 4 μL / min / million cells.In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein and b) an in vitro metabolic clearance of human and mouse hepatocytes of less than about 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM and MLM in vitro metabolic clearance of less than 12 μL / min / mg protein and b) an in vitro metabolic clearance of human and mouse hepatocytes of less than 4 μL / min / million cells. In certain embodiments, a compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has a) an HLM and MLM in vitro metabolic clearance of less than 12 μL / min / mg protein and b) an in vitro metabolic clearance of human and mouse hepatocytes of less than 4 μL / min / million cells.
[0868] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 20 μL / min / mg protein and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 20 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 15 μL / min / mg protein and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 17 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 12 μL / min / mg protein, and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 7 μL / min / million cells. In another embodiment, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an HLM and MLM in vitro metabolic clearance of less than about 11.55 μL / min / mg protein, and an in vitro metabolic clearance of human and mouse hepatocytes of less than about 3.85 μL / min / million cells.
[0869] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 120 minutes. In some embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 110 minutes. In some embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 100 minutes. In some embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 90 minutes. In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 80 minutes.In some embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human, mouse, rat, monkey, or dog microsomes of greater than about 70 minutes.
[0870] In another embodiment, the compound of the disclosure is any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human microsomes of greater than about 120 minutes.
[0871] In another embodiment, the compound of the disclosure is any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse microsomes of greater than about 120 minutes.
[0872] In certain embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 120 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 110 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 100 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 90 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat microsomes of greater than about 80 minutes.In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 70 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 60 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat microsomes of greater than about 50 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat microsomes of greater than about 40 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat microsomes of greater than about 30 minutes.In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 20 minutes. In some embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro rat microsomal half-life of greater than about 10 minutes. In one embodiment, the compound is selected from any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0873] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 360 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 350 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 325 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 310 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 300 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 290 minutes.In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 250 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 200 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 150 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 100 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in human hepatocytes of greater than about 80 minutes. In one embodiment, the compound is selected from any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0874] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 360 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 350 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 325 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 300 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 250 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 225 minutes.In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 200 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 150 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 100 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 50 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mouse hepatocytes of greater than about 30 minutes. In one embodiment, the compound is selected from any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0875] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 360 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 350 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 325 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 300 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 250 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 225 minutes.In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 200 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 150 minutes. In one embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 100 minutes. In one embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in rat hepatocytes of greater than about 50 minutes. In one embodiment, the compound has an in vitro half-life in rat hepatocytes of greater than about 30 minutes. In one embodiment, the compound is selected from any of the compounds of Tables A and B or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0876] In certain embodiments, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro half-life stability in mammalian microsomes of greater than 80 minutes. In one embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro half-life stability in mammalian microsomes of greater than 90 minutes. In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro half-life stability in mammalian microsomes of greater than 100 minutes. In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro half-life stability in mammalian microsomes of greater than 110 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes of greater than 115 minutes.In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro half-life stability in mammalian microsomes of greater than 120 minutes. In one embodiment, the compound is selected from any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In one embodiment, the mammalian microsomes are human or mouse microsomes.
[0877] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and have an in vitro half-life stability in mammalian microsomes ranging from about 50 minutes to about 200 minutes. In one embodiment, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and have an in vitro half-life stability in mammalian microsomes ranging from about 80 minutes to about 180 minutes. In one embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes in the range of about 100 minutes to about 160 minutes. In one embodiment, the disclosed compound is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes in the range of about 110 minutes to about 150 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes that is in the range of about 110 minutes to about 140 minutes.In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes in the range of about 110 minutes to about 130 minutes. In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life stability in mammalian microsomes in the range of about 115 minutes to about 130 minutes. In another embodiment, the compound of the disclosure is any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and has an in vitro half-life stability in mammalian microsomes ranging from about 115 minutes to about 130 minutes. In one embodiment, the mammalian microsomes are human or mouse microsomes.
[0878] In one embodiment, the disclosure provides compounds that demonstrate blocking androgen-induced PSA-luciferase activity (PSA-luciferase assay). In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro IC of less than about 4500 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 4000 nM in a PSA-luciferase assay.50 In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 3500 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 3000 nM in a PSA-luciferase assay. 50 In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 2500 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 2000 nM in a PSA-luciferase assay. 50 In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 1500 nM in a PSA-luciferase assay. 50In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 950 nm in a PSA-luciferase assay. 50 In one embodiment, the compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 900 nM in a PSA-luciferase assay. 50 It has.
[0879] In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 890 nM, less than about 880 nM, less than about 870 nM, less than about 860 nM, less than about 850 nM, less than about 840 nM, less than about 830 nM, less than about 820 nM, less than about 810 nM, or less than about 800 nM in a PSA-luciferase assay. 50In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 790 nM, less than about 780 nM, less than about 770 nM, less than about 760 nM, less than about 750 nM, less than about 740 nM, less than about 730 nM, less than about 720 nM, less than about 710 nM, or less than about 700 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 690 nM, less than about 680 nM, less than about 670 nM, less than about 660 nM, less than about 650 nM, less than about 640 nM, less than about 630 nM, less than about 620 nM, less than about 610 nM, or less than about 600 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 590 nM, less than about 580 nM, less than about 570 nM, less than about 560 nM, less than about 550 nM, less than about 540 nM, less than about 530 nM, less than about 520 nM, less than about 510 nM, or less than about 500 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 500 nM in a PSA-luciferase assay.50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 490 nM, less than about 480 nM, less than about 470 nM, less than about 460 nM, less than about 450 nM, less than about 440 nM, less than about 430 nM, less than about 420 nM, less than about 410 nM, or less than about 400 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 390 nM, less than about 380 nM, less than about 370 nM, less than about 360 nM, less than about 350 nM, less than about 340 nM, less than about 330 nM, less than about 320 nM, less than about 310 nM, or less than about 300 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 290 nM, less than about 280 nM, less than about 270 nM, less than about 260 nM, less than about 250 nM, less than about 240 nM, less than about 230 nM, less than about 220 nM, less than about 210 nM, or less than about 200 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC of less than about 200 nM in a PSA-luciferase assay. 50 In one embodiment, the compound is selected from any of the compounds of Tables A and B or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0880] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 80 minutes and an in vitro IC of less than about 2000 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 90 minutes and an in vitro IC of less than about 1500 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 100 minutes and an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 105 minutes and an in vitro IC of less than about 900 nM in a PSA-luciferase assay. 50In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 110 minutes and an in vitro IC of less than about 850 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 115 minutes and an in vitro IC of less than about 800 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 115 minutes and an in vitro IC of less than about 750 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 120 minutes and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 120 minutes and an in vitro IC of less than about 650 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 120 minutes and an in vitro IC of less than about 600 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 120 minutes and an in vitro IC of less than about 550 nM in a PSA-luciferase assay. 50 In one embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro half-life in mammalian microsomes of greater than about 120 minutes and an in vitro IC of less than about 500 nM in a PSA-luciferase assay. 50 In one embodiment, the compound is selected from any of the compounds of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. In one embodiment, the mammalian microsomes are human or mouse microsomes.
[0881] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 and an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 and HLM and MLM in vitro metabolic clearance of less than 12 μL / min / mg protein. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 and an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 and has an in vitro metabolic clearance in human and mouse hepatocytes of less than 4 μL / min / million cells.
[0882] In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 , an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein, and an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 800 nM in a PSA-luciferase assay. 50 , an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein, and an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells. In another embodiment, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, or a compound of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50 , an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein, and an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells. In one embodiment, the compound is selected from any of the compounds of Tables A and B or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof.
[0883] In certain embodiments, the compound of the disclosure is a compound of any of Tables A and B, or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compound has an in vitro IC of less than about 1000 nM in a PSA-luciferase assay. 50 , with an HLM or MLM in vitro metabolic clearance of less than 12 μL / min / mg protein, and an in vitro metabolic clearance of human or mouse hepatocytes of less than 4 μL / min / million cells.
[0884] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro metabolic clearance of HH of less than 4 μL / min / million cells. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro metabolic clearance of HH of less than 4 μL / min / million cells and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro metabolic clearance of HH of less than 4 μL / min / million cells and an in vitro IC of less than about 675 nM in a PSA-luciferase assay. 50 In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro half-life of HH of less than about 350 minutes. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro half-life of HH of greater than about 320 minutes and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50In one embodiment, the compound has an in vitro half-life of HH of greater than about 350 minutes and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50 It has.
[0885] In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro metabolic clearance of MLM of less than 15 μL / min / mg protein. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro metabolic clearance of MLM of less than 15 μL / min / mg protein and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro metabolic clearance of MLM of less than 15 μL / min / mg protein and an in vitro IC of less than about 675 nM in a PSA-luciferase assay. 50 In certain embodiments, the disclosed compounds have the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of MH of less than 10 μL / min / million cells. In one embodiment, the compounds have an in vitro metabolic clearance of MH of less than 8 μL / min / million cells. In certain embodiments, the disclosed compounds have the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro metabolic clearance of MH of less than 10 μL / min / million cells and an in vitro IC of less than about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro metabolic clearance of less than 8 μL / min / million cells MH and an in vitro IC of less than about 675 nM in a PSA-luciferase assay. 50In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro half-life of MLM of greater than about 100 minutes. In certain embodiments, the disclosed compounds are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compounds have an in vitro half-life of MLM of greater than about 100 minutes. In one embodiment, the compounds have an in vitro half-life of MLM of greater than about 180 minutes.
[0886] In certain embodiments, a compound of the present disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro metabolic clearance of MH that is within the range of 3 μL / min / million cells to about 20 μL / min / million cells. In one embodiment, the compound has an in vitro metabolic clearance of MH that is within the range of 3.2 μL / min / million cells to about 18 μL / min / million cells. In one embodiment, the compound has an in vitro metabolic clearance of MH that is within the range of 3.4 μL / min / million cells to about 17 μL / min / million cells.
[0887] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than 650 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC of less than about 640 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC of less than about 635 nM in a PSA-luciferase assay. 50 It has.
[0888] In certain embodiments, the compounds of the disclosure are compounds having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, and the compounds have an in vitro IC in the range of 200 nM to about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC ranging from about 250 nM to about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC in the range of about 300 nM to about 700 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC ranging from about 350 nM to about 675 nM in a PSA-luciferase assay. 50 It has.
[0889] In certain embodiments, a compound of the disclosure is a compound having the structure of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the compound has an in vitro IC of less than 525 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC of less than about 500 nM in a PSA-luciferase assay. 50 In one embodiment, the compound has an in vitro IC of less than about 450 nM in a PSA-luciferase assay. 50 It has.
[0890] Pharmaceutical Compositions and Formulations The present disclosure also includes pharmaceutical compositions for modulating the androgen receptor (AR) in a subject. In one embodiment, the pharmaceutical composition comprises one or more compounds of Formulas (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt or solvate thereof.
[0891] In one embodiment of the present disclosure, the pharmaceutical composition comprises a therapeutically effective amount of one or more compounds of Formulae (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt or solvate thereof.
[0892] In certain embodiments, pharmaceutical compositions as described herein comprise one or more compounds selected from Table A, or pharmaceutically acceptable salts or solvates thereof. In one embodiment, pharmaceutical compositions as described herein comprise one or more compounds selected from Table B, or pharmaceutically acceptable salts or solvates thereof.
[0893] In certain embodiments, a pharmaceutical composition as described herein comprises one or more compounds selected from compound A3, A5, A7, A13, A17, A18, A22, A23, A24, A25, A28, A30, A31, A32, A34, A35, A38, A40, A41, A42, A45, A49, A52, A53, A54, A56, A57, A58, A62, A63, A64, A65, A68, A73, A74, A75, A76, B1, B2, B3, or B6, or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the pharmaceutical compositions as described herein comprise compounds A1, A2, A4, A6, A8, A9, A10, A11, A12, A14, A15, A16, A19, A20, A21, A26, A27, A29, A33, A36, A37, A39, A43, A44, A46, A47, A48, A50, A51, A55, A59, A60, A61, A66, A67, A68, A69, A70, A71, A72, A73, A74, A75, A76, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, A98, A99, A100, A101, A102, A103, A104, A105, A106, A107, A108, A109, A110, A111, A112, A113, A114, A115, A116, A117, A118, A119, A20, A21, A22, A23, A24, A25, A26, A27, A28, A29, A33, A36, A37, A39, A43, A44, A46, A47, A48, A50, A51, A55, A59, A60, A61, A62, A63, A64, A65, A66, A67, A68, A69, A70, A
[0023] In certain embodiments, the pharmaceutical composition as described herein comprises one or more compounds selected from compounds A69, A70, A71, A72, A77, A78, A79, A80, A81, A82, A83, A84, A85, A86, A87, A88, A89, A90, A91, A92, A93, A94, A95, A96, A97, B4, B5, B7, B8, B9, B10, or B11, or a pharmaceutically acceptable salt or solvate thereof. In certain embodiments, the pharmaceutical composition as described herein comprises one or more compounds selected from compounds A98-A186. In certain embodiments, the pharmaceutical composition as described herein comprises one or more compounds selected from compounds A187-A211. In certain embodiments, the pharmaceutical composition as described herein comprises one or more compounds selected from compounds A212-A234. In certain embodiments, a pharmaceutical composition as described herein comprises one or more compounds selected from compounds A1-A96, A98-A116, A118-A159, A161-A175, and A177-A234.In certain embodiments, pharmaceutical compositions as described herein comprise one or more compounds selected from compounds A13, A57, A74, A93, A109, A112, A122, A126, A131, A134, A136, A137, A164, A168, A169, A170, A171, A172, A184, A185, A195, and / or A204, or pharmaceutically acceptable salts, tautomers, stereoisomers, or prodrugs thereof. In certain embodiments, pharmaceutical compositions as described herein comprise one or more compounds selected from compounds A1-A211 or B1-B11. In certain embodiments, pharmaceutical compositions as described herein comprise one or more compounds selected from compounds A1-A234 or B1-B11.
[0894] In one embodiment, a pharmaceutical composition as described herein comprises one or more compounds of Formulae (I)-(VI) and / or (A)-(HI), or a pharmaceutically acceptable salt or solvate thereof, and further comprises one or more additional therapeutically active agents. In one embodiment, the one or more additional therapeutically active agents are selected from therapeutic agents useful for treating cancer, neurological diseases, disorders characterized by abnormal accumulation of alpha-synuclein, disorders of the aging process, cardiovascular diseases, bacterial infections, viral infections, mitochondrial-related diseases, mental retardation, deafness, blindness, diabetes, obesity, autoimmune diseases, glaucoma, Leber's hereditary optic neuropathy, and rheumatoid arthritis.
[0895] In some embodiments, the one or more additional therapeutic agents are poly(ADP-ribose) polymerase (PARP) inhibitors, including but not limited to, olaparib, niraparib, rucaparib, talazoparib; androgen receptor ligand binding domain inhibitors, including but not limited to, enzalutamide, apalutamide, darolutamide, bicalutamide, nilutamide, flutamide, ODM-204, TAS3681; inhibitors of CYP17, including but not limited to, galeterone, abiraterone, abiraterone acetate. microtubule inhibitors, such as, but not limited to, docetaxel, paclitaxel, cabazitaxel (XRP-6258); PD-1 or PD-L1 modulators, such as, but not limited to, pembrolizumab, durvalumab, nivolumab, atezolizumab; gonadotropin-releasing hormone agonists, such as, but not limited to, cyproterone acetate, leuprolide; 5-alpha reductase inhibitors, such as, but not limited to, finasteride, dutasteride, turosteride, bexlosteride, izonsteride, FCE 28260, SKF105, 111, vascular endothelial growth factor inhibitors, such as but not limited to bevacizumab (Avastin), histone deacetylase inhibitors, such as but not limited to OSU-HDAC42, integrin alpha-v-beta-3 inhibitors, such as but not limited to VITAXIN, receptor tyrosine kinase inhibitors, such as but not limited to sunitinib, phosphoinositide 3 kinase inhibitors, including but not limited to alpelisib, buparlisib, idelalisib; anaplastic lymphoma kinase (ALK) inhibitors, including but not limited to crizotinib, alectinib; endothelin receptor A antagonists, including but not limited to ZD-4054; anti-CTLA4 inhibitors, including but not limited to MDX-010 (ipilimumab); heat shock protein 27 (HSP27) inhibitors, including but not limited to OGX427, androgen receptor degraders, such as, but not limited to, ARV-330, ARV-110, androgen receptor DNA binding domain inhibitors, such as, but not limited to, VPC-14449, bromodomain and extra terminal motif (BET) inhibitors, such as, but not limited to, BI-894999, GSK25762, GS-5829, androgen receptor N-terminal domain inhibitors, such as, but not limited to, sintokamide. alpha particle emitting radiotherapeutic agents, including but not limited to radium 233 or its salts, niclosamide or its related compounds, selective estrogen receptor modulators (SERMs), including but not limited to tamoxifen, raloxifene, toremifene, arzoxifene, bazedoxifene, pippindoxifene, lasofoxifene, enclomiphene, selective estrogen receptor degraders (SERDs), including but not limited to fulvestrant, ZB71 6, including but not limited to OP-1074, elacestrant, AZD9496, GDC0810, GDC0927, GW5638, GW7604, aromatase inhibitors, including but not limited to anastrazole, exemestane, letrozole, selective progesterone receptor modulators (SPRMs), such as mifepristone, lonaprison, onapristone, asoprisnil, lonaprisnil, ulipristal, telapristone, glucosides, Ruticoid receptor inhibitors, including but not limited to mifepristone, COR108297, COR125281, ORIC-101, and PT150; CDK4 / 6 inhibitors, including but not limited to palbociclib, abemaciclib, and ribociclib; HER2 receptor antagonists, including but not limited to trastuzumab and neratinib; and mammalian target of rapamycin (mTOR) inhibitors, including but not limited to everolimus and temsirolimus.
[0896] In a further embodiment of the present disclosure, there is provided a pharmaceutical composition comprising one or more compounds of Formulae (I)-(VI) and / or (A)-(HI), or pharmaceutically acceptable salts or solvates thereof, and a pharmaceutically acceptable excipient or adjuvant. Pharmaceutically acceptable excipients and adjuvants are added to compositions or formulations for a variety of purposes. In another embodiment, a pharmaceutical composition comprising one or more compounds of Formulae (I)-(VI) and / or (A)-(HI), or pharmaceutically acceptable salts or solvates thereof, further comprises a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutically acceptable carrier comprises a pharmaceutically acceptable excipient, binder, and / or diluent. In one embodiment, suitable pharmaceutically acceptable excipients include, but are not limited to, water, saline,...
Claims
1. Formula (A-I): 【Chemistry 1】 or a pharma- ceutically acceptable salt, tautomer or stereoisomer thereof, wherein C is a 5- to 7-membered heteroaryl ring; X is -(CR 5 R 6 ) t - or -NR 7 and Y is a bond, -(CR 8 R 9 ) m -, -O-, -S-, -S(=O)-, -SO 2 --, --NR 7 -, or -N(COCH 3 ) - and W is a bond, -(CR 8a R 9a ) m -, -C(=O)-, -N(R 7 )CO-,-CONR 7 - or -NSO 2 R 7 - and Z is a bond, -CH 2 -, -C(CH 3 )H-, -O-, -S-, -NH-, -NCH 3 -, or -N(COCH 3 ) - and V is -CH 2 -, and L is halogen, -NH 2 , -CHCl 2 , -CCl 3 , or -CF 3 or V is -CH 2 CH 2 -, and L is halogen or -NH 2 and R 1 and R 2 each independently represents hydrogen, halogen, -CN, -CF 3 , —OH, optionally substituted C 1 ~C 6 Alkyl, optionally substituted C 1 ~C 6 Alkoxy, optionally substituted -(C 1 ~C 6 alkyl)-(C 1 ~C 6 alkoxy), optionally substituted -(C 1 ~C 6 alkyl)-OH, -NR 13 R 14 , optionally substituted -(C 1 ~C 6 alkyl)-NR 13 R 14 , -NR 14 SO 2 R 16 , optionally substituted -(C 1 ~C 6 alkyl)NR 14 SO 2 R 16 , -NR 14 C.O.R. 16 , optionally substituted -(C 1 ~C 6 alkyl)-NR 14 C.O.R. 16 , -CONR 13 R 14 , optionally substituted -(C 1 ~C 6 (alkyl)-CONR 14 R 15 , -SO 2 N.R. 14 R 15 , optionally substituted -(C 1 ~C 6 (alkyl)-SO 2 N.R. 14 R 15 , optionally substituted -SO 2 R 16 or optionally substituted -(C 1 ~C 6 (alkyl)-SO 2 R 16 and At least one R 3 But -CN, -CF 3 , -S(C 1 ~C 3 Alkyl), -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -NHSO 2 CF 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N (CH 3 ) S.O. 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), -NHCO(C 1 ~C 3 alkyl), or -N(CH 3 ) COO (C 1 ~C 3 alkyl), and other R 3 When present, halogen, oxo, =S, =NR 16 , -CN, -CF 3 , -OH, -S(C 1 ~C 3 Alkyl), C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 1 ~C 3 Alkoxy, -NR 13 R 14 , -(C 1 ~C 3 alkyl)-NR 13 R 14 , -NR 14 SO 2 R 16 , -(C 1 ~C 3 alkyl)NR 14 SO 2 R 16 , -NR 14 C.O.R. 16 , -(C 1 ~C 6 alkyl)-NR 14 C.O.R. 16 , -CONR 14 R 15 , -(C 1 ~C 3 (alkyl)-CONR 14 R 15 , -SO 2 N.R. 14 R 15 , -(C 1 ~C 3 (alkyl)-SO 2 N.R. 14 R 15 , -SO 2 (C 1 ~C 3 alkyl), or -(C 1 ~C 6 (alkyl)-SO 2 (C 1 ~C 3 alkyl), R 5 and R 6 each independently represents hydrogen, halogen, —OH, C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl or C 1 ~C 3 Alkoxy or R 5 and R 6 together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl; R 7 is hydrogen, C 1 ~C 6 Alkyl, C 2 ~C 6 Alkenyl, or C 2 ~C 6 is alkynyl, R 8 and R 9 are each independently hydrogen, halogen, or C 1 ~C 3 is alkyl, R 8a and R 9a each independently represents hydrogen, —OH, halogen, C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 1 ~C 3 Alkoxy, -NR 13 R 14 , -(C 1 ~C 3 alkyl)-NR 13 R 14 , -NR 14 C.O.R. 16 , -(C 1 ~C 3 alkyl)-NR 14 C.O.R. 16 , -CONR 14 R 15 , or -(C 1 ~C 3 (alkyl)-CONR 14 R 15 or R 8a and R 9a together form an optionally substituted 3- to 6-membered carbocyclyl or heterocyclyl; R 13 , R 14 and R 15 each independently represents hydrogen, C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, or C 2 ~C 3 alkynyl or R 14 and R 15 together form a 3- to 6-membered heterocyclyl, R 16 is hydrogen, optionally substituted C 1 ~C 3 Alkyl, optionally substituted C 2 ~C 3 Alkenyl, optionally substituted C 2 ~C 3 Alkynyl, C 3 ~C 6 cycloalkyl, or phenyl; each m is independently 0 or 1; n1 and n2 are each independently 0, 1, or 2; n3 is 1, 2, 3, 4 or 5; The compound or a pharma- ceutically acceptable salt, tautomer, or stereoisomer thereof, wherein t is 1 or 2.
2. C is (R 3 2. The compound of claim 1, wherein n is a pyrazole, imidazole, oxazole, oxadiazole, oxazolone, isoxazole, thiazole, pyridyl, pyrazine, furan or pyrimidyl substituted with n3.
3. C is (R 3 ) is substituted with n3, 【Chemistry 2】 wherein R 3a C 1 ~C 3 alkyl, and n3 is 1 or 2; The compound of claim 1.
4. X is -(CR 5 R 6 ) t - and Y and Z are each —O—; V is -CH 2 - or -CH 2 CH 2 - and L is a halogen; R 1 and R 2 each independently represents hydrogen, halogen, -CN, -CF 3 , —OH, or optionally substituted C 1 ~C 6 is alkyl, R 5 and R 6 each independently represents hydrogen, halogen, —OH, or C 1 ~C 3 is alkyl, R 16 is hydrogen, C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, or C 2 ~C 3 The compound of claim 1 which is alkynyl.
5. R 5 and R 6 are each independently hydrogen or C 1 ~C 3 is alkyl, W is -CH 2 - or -C(CH 3 ) H-; V is -CH 2 CH 2 - and R 1 and R 2 The compound of claim 4, wherein each is independently hydrogen, halogen, or -CN.
6. During the ceremony, C is a 5-7 membered monocyclic heteroaryl containing 1, 2 or 3 heteroatoms selected from O, S, or N as ring members; X is -(CR 5 R 6 ) t - or -NR 7 and Y is a bond, -CH 2 -, -C(CH 3 )H-, -O-, -S-, -NH-, -NCH 3 -, or -N(COCH 3 ) - and Z is a bond, -CH 2 -, -O-, or -NH-; W is a bond, -CH 2 -, -C(CH 3 )H-, -C(=O)-, -N(R 7 ) CO- or -CONR 7 - and V is -CH 2 -, and L is halogen, -NH 2 , or -CF 3 or V is -CH 2 CH 2 -, and L is halogen or -NH 2 and R 1 and R 2 each independently represents hydrogen, halogen, -CN, -CF 3 , methyl, or -CONH 2 and At least one R 3 But -CN, -CF 3 , -S(C 1 ~C 3 Alkyl), -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -NHSO 2 CF 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N (CH 3 ) S.O. 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), -NHCO(C 1 ~C 3 alkyl), or -N(CH 3 ) COO (C 1 ~C 3 alkyl), and other R 3 If present, -CN, C 1 ~C 3 Alkoxy, -CF 3 , C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, -S(C 1 ~C 3 Alkyl), -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N (CH 3 ) S.O. 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), or -NHCO(C 1 ~C 3 alkyl), R 5 and R 6 each independently represents hydrogen, halogen, —OH, or C 1 ~C 3 is alkyl, R 7 is H or C 1 ~C 6 is alkyl, n1 and n2 are each independently 0, 1, or 2; n3 is 1, 2, 3, 4 or 5; The compound of claim 1 , wherein t is 1 or 2.
7. At least one R 3 , -CN, -CONH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , or -SO 2 CH 3 and other R 3 When present, -CN, -CF 3 , C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 1 ~C 3 Alkoxy, -S(C 1 ~C 3 Alkyl), -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N (CH 3 ) S.O. 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), or -NHCO(C 1 ~C 3 2. The compound of claim 1, wherein the aryl group is selected from the group consisting of aryl, ... and alkyl.
8. X is -(CR 5 R 6 ) t and W is a bond, -CH 2 - or -C(CH 3 ) H-; Y is -O-, Z is -O-, V is -CH 2 - or -CH 2 CH 2 - and The compound of claim 1 , wherein L is a halogen.
9. The compound represented by formula (G-II) 【Chemistry 3】 or a pharma- ceutically acceptable salt, tautomer or stereoisomer thereof, wherein: C, 【Chemistry 4】 and X is -(CR 5 R 6 ) t - and Y is -O-, Z is -O-, W is -CH 2 - or -C(CH 3 ) H-; V is -CH 2 CH 2 - and L is a halogen; R 1 and R 2 are each independently Cl or -CN; At least one R 3 , -CN, -CONH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , or -SO 2 CH 3 and other R 3 When present, -CN, -CF 3 , C 1 ~C 3 Alkyl, C 2 ~C 3 Alkenyl, C 2 ~C 3 Alkynyl, C 1 ~C 3 Alkoxy, -S(C 1 ~C 3 Alkyl), -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -CH 2 N.H.S.O. 2 CH 3 , -CH 2 N (CH 3 ) S.O. 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), or -NHCO(C 1 ~C 3 alkyl), R 5 and R 6 are each independently hydrogen or methyl; n1 and n2 are each independently 0, 1, or 2; n3 is 1 or 2; The compound of claim 1 , wherein t is 1.
10. At least one R 3 But -NHSO 2 CH 3 , -NHSO 2 CH 2 CH 3 , or -SO 2 CH 3 and other R 3 If present, -CN, C 1 ~C 3 Alkyl, C 1 ~C 3 Alkoxy, -SO 2 (C 1 ~C 3 Alkyl), -NH 2 , -(C 1 ~C 3 alkyl)NH 2 , -NHSO 2 CH 3 , -N(CH 3 ) S.O. 2 CH 3 , -NHSO 2 CH 2 CH 3 , -N(CH 3 ) S.O. 2 CH 2 CH 3 , -SO 2 N.H. 2 , -CONH 2 , -CON(C 1 ~C 3 Alkyl) 2 , -CONH(C 1 ~C 3 alkyl), or -NHCO(C 1 ~C 3 10. The compound of claim 9, wherein the aryl group is selected from the group consisting of aryl, ... and alkyl.
11. 【Chemical 5-1】 【Chemistry 5-2】 【Chemistry 5-3】 【Chemistry 5-4】 【Chemistry 5-5】 【Chemistry 5-6】 【Chemistry 5-7】 【Chemistry 5-8】 【Chemistry 5-9】 【Chemistry 5-10】 【Chemistry 5-11】 【Chemistry 5-12】 【Chemistry 5-13】 【Chemistry 5-14】 【Chemistry 5-15】 【Chemistry 5-16】 【Chemistry 5-17】 【Chemistry 5-18】 or a pharma- ceutically acceptable salt, tautomer or stereoisomer thereof.
12. The compound is 【Chemistry 6-1】 【Chemistry 6-2】 12. The compound of claim 11, which is selected from:
13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 10 and a pharma- ceutically acceptable carrier.
14. 12. A pharmaceutical composition comprising a compound of claim 11 and a pharma- ceutically acceptable carrier.
15. 13. A pharmaceutical composition comprising a compound of claim 12 and a pharma- ceutically acceptable carrier.
16. A compound having the structure: or a pharma- ceutically acceptable salt thereof. 【Chemistry 7】
17. 17. A pharmaceutical composition comprising a compound of claim 16 or a pharma- ceutically acceptable salt thereof and a pharma- ceutically acceptable carrier.
18. 17. A compound according to claim 16, or a pharma- ceutically acceptable salt thereof, for use in the treatment of cancer.
Citation Information
Patent Citations
Trifluoroethoxypyri(mi)din derivatives and liquid-crystalline medium
DE4326393A1
Heterocyclic compounds and methods of their use for cancer imaging and therapy
JP2018502867A
Diamine derivatives as inhibitors of leukotriene a4 hydrolase
WO2007079078A1
Biaryl inhibitors of the sodium channel
WO2013131018A1
Multicyclic compounds and methods of using same
WO2015042414A1
